PALM INTRANET

Day : Monday
Date: 4/14/2003
Time: 13:35:45

Inventor Name Search Result

Your Search was:

Last Name = BABA
First Name = MASANORI

Application#	Patent#	Status	Date Filed	Title	Inventor Name
60104847	Not Issued	159	10/16/1998	CCR5 ANTAGONIST COMPRISING ANILIDE DERIVATIVES	BABA , MASANORI
60104845	Not Issued	159	10/16/1998	QUATERNARY AMMONIUM SALTS AND THEIR USE	BABA , MASANORI
10275417	Not Issued	030	11/04/2002	HIV-PRODUCING CELL LINE AND USES THEREOF	BABA, MASANORI
10273111	Not Issued	030	10/18/2002	CYCLIC AMINE COMPOUNDS AS CCR5 ANTAGONISTS	BABA, MASANORI
10089961	Not Issued	030	04/05/2002	UREA COMPOUNDS,PROCESS FOR PRODUCING THE SAME AND USE THEREOF	BABA, MASANORI
10089374	Not Issued	095	03/29/2002	CYCLIC AMINE COMPOUNDS AS CCR5 ANTAGONISTS	BABA, MASANORI
10030332	Not Issued	071	02/15/2002	CYCLIC AMIDE COMPOUNDS, PROCESS FOR THE PREPARATION OF THE SAME AND USES THEREOF	BABA, MASANORI
10018321	Not Issued	030	12/12/2001	BENZAZEPINE DERIVATIVES, PROCESS FOR YHE PREPARATION OF THE SAME AND USES THEREOF	BABA, MASANORI
09980773	Not Issued	041	11/02/2001	CYCLIC COMPOUNDS AND USES THEREOF	BABA, MASANORI
09661320	6268354	150	09/13/2000	PHARMACEUTICAL COMPOSITION FOR ANTAGONIZING CCR5 COMPRISING ANILIDE DERIVATIVE	BABA, MASANORI
09624119	Not Issued	030	07/24/2000	IMPULSE NOISE REJECTION CIRCUIT AND SATELLITE COMMUNICATIONS TERMINAL USING THE SAME	BABA, MASANORI
09580270	6376536	150	05/26/2000	QUATERNARY AMMONIUM	BABA,

				SALTS AND THEIR USE	MASANORI
09463924	6235771	150	03/27/2000	ANILIDE DERIVATIVE, PRODUCTION AND USE THEREOF	BABA, MASANORI
09377040	6096780	150	08/19/1999	QUATERNARY AMMONIUM SALTS AND THEIR USE	BABA , MASANORI
09213377	6172061	150	12/17/1998	PHARMACEUTICAL COMPOSITION FOR ANTAGONIZING CCR5 COMPRISING ANILIDE DERIVATIVE	BABA , MASANORI
09043871	5945514	150	03/30/1998	ANTIVIRAL RAW MATERIALS	BABA , MASANORI
09037712	6123943	150	03/10/1998	NF-KB ACTIVITY INHIBITOR	BABA , MASANORI
08957358	RE37979	150	10/23/1997	PYRIMIDINE DERIVATIVES AND ANTI-VIRAL AGENT CONTAINING THE SAME AS ACTIVE INGREDIENT THEREOF	BABA , MASANORI
08809836	5948916	150	06/09/1997	ARYLTHIADIAZOLE DERIVATIVE AND ANTIVIRAL AGENT CONTAINING	BABA , MASANORI
08222071	5461060	150	09/03/1993	PYRIMIDINE DERIVATIVES AND ANTI-VIRAL AGENT CONTAINING THE SAME AS ACTIVE INGREDIENT THEREOF	BABA , MASANORI
08110322	5596018	150	08/20/1993	ANTIVIRAL AGENTS AGAINST AIDS-CAUSING VIRUS	BABA , MASANORI
07830924	Not Issued	161	02/04/1992	ANTI-VIRUS AGENT	BABA , MASANORI
07830922	5264621	150	02/04/1992	ANTI-VIRUS AGENT	BABA , MASANORI
07830914	Not Issued	161	02/04/1992	ANTI-VIRUS AGENT	BABA , MASANORI
07821021	5292505	150	01/15/1992	SULPHATED VINYL POLYMERS IN COMPOSITIONS FOR TREATING RETROVIRAL INFECTIONS	BABA , MASANORI
07676912	5318972	150	03/28/1991	PYRIMIDINE NUCLEOSIDE DERIVATIVE AND ANTIVIRAL AGENT CONTAINING THE DERIVATIVE AS ACTIVE INGREDIENT	BABA , MASANORI
07600155	Not	161	10/17/1990	THERAPEUTIC APPLICATION	BABA ,

	Issued			OF DIDEOXYTHYMIDINE AND DIDEOXYTHYMIDIENE	MASANORI
07590475	Not Issued	166	09/28/1990	6-SUBSTITUTED ACYCLOPYRIMIDINE NUCLEOSIDE DERIVATIVES AND ANTIVIRAL AGENT CONTAINING THE SAME AS ACTIVE INGREDIENT THEREOF	BABA , MASANORI
07566450	Not Issued	166	12/18/1991	ANTIVIRAL AGENTS AGAINST AIDS-CAUSING VIRUS	BABA , MASANORI
07531462	Not Issued	161	05/31/1990	METHOD FOR INHIBITING THE PROLIFERATION OF HIV VIRUSES AND ACTIVATING THE IMMUNO-ENHANCEMAENT IN HOST INFECTED WITH HIV VIRUSES	BABA , MASANORI
07449930	5112835	150	11/21/1989	6-SUBSTITUTED ACYCLOPYRIMIDINE NUCLEOSIDE DERIVATIVES AND ANTIVIRAL AGENTS CONTAINING THE SAME AS ACTIVE INGREDIENT THEREOF	BABA , MASANORI
07387507	Not Issued	161	07/28/1989	THERAPEUTIC AND PROPHYLACTIC APPLICATION OF DEXTRAN SULFATE AND HEPARIN AGAINST AIDS	BABA , MASANORI
07315413	5152978	150	02/23/1989	SULPHATED VINYL POLYMERS IN COMPOSITIONS FOR TREATING RETROVIRAL INFECTIONS	BABA , MASANORI
07068843	Not Issued	161	07/01/1987	ANTIVIRAL AGENT FOR INHIBITING GROWTH OF VIRUS OF ACQUIRED IMMUNE DEFICIENCY SYNDROME (AIDS)	BABA , MASANORI
07057008	Not Issued	161	06/02/1987	THERAPEUTIC AND PROPHYLACTIC APPLICATION OF DEXTRAN SULFATE AND HEPARIN AGAINST AIDS	BABA , MASANORI
07043706	Not Issued	166	04/29/1987	THERAPEUTIC APPLICATION OF DIDEOXYTHYMIDINE AND DIDEOXYTHYMIDINENE	BABA , MASANORI
06135180	4348566	150	03/28/1980	RHODIUM ELECTRICAL CONTACT OF A SWITCH PARTICULARLY A REED	BABA , MASANORI

SWITCH

Inventor Search Completed: No Records to Display.

Search Another: Inventor

Last Name Baba

First Name masanori

Search

To go back use Back button on your browser toolbar.

Back to PALM | ASSIGNMENT | OASIS | Home page

AN 2001:228848 CAPLUS
DN 134:266103
TI Preparation of N-tetrahydronaphthalenyl carboxamides as melanin concentrating hormone antagonists
IN Kato, Kaneyoshi; Terauchi, Jun; Mori, Masaaki; Suzuki, Nobuhiro; Shimomura, Yukio; Takekawa, Shiro; Ishihara, Yuji
PA Takeda Chemical Industries, Ltd., Japan
SO PCT Int. Appl., 363 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001021577	A2	20010329	WO 2000-JP6375	20000919
	WO 2001021577	A3	20011004		
	W: AE, AG, AL, AM, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CN, CR, CU, CZ, DM, DZ, EE, GD, GE, HR, HU, ID, IL, IN, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LV, MA, MD, MG, MK, MN, MX, MZ, NO, NZ, PL, RO, RU, SG, SI, SK, TJ, TM, TR, TT, UA, US, UZ, VN, YU, ZA, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	EP 1218336	A2	20020703	EP 2000-961075	20000919
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				
	JP 2002003370	A2	20020109	JP 2000-290357	20000920
PRAI	JP 1999-266298	A	19990920		
	JP 1999-357889	A	19991216		
	JP 2000-126272	A	20000420		
	WO 2000-JP6375	W	20000919		

OS MARPAT 134:266103
GI



I



II

AB The title compds. [I; Ar1 = (un)substituted cyclic group; X = a spacer having a main chain of 1-6 atoms; Y = a bond, a spacer having a main chain of 1-6 atoms; Ar = (un)substituted monocyclic arom. ring which may be

condensed with a 4-8 membered non-arom. ring; R1, R2 = H, a hydrocarbon group which may have substituents; NR1R2 may form a (un)substituted nitrogen-contg. hetero ring; R2 may form a spiro ring together with Ar; R2, together with the adjacent nitrogen atom and Y, may form a (un)substituted nitrogen-contg. hetero ring] and their salts, useful as agents for preventing or treating obesity, were prepd. and formulated. Thus, reacting 6-amino-2-[(dimethylamino)methyl]tetralin with 4-(4-methoxyphenyl)benzoic acid in the presence of HOBt, WSCD, Et3N and DMAP in DMF afforded the carboxamide II which showed IC50 of 40 nM in GTPgS binding assay.

IT **331756-17-3P**

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of N-tetrahydronaphthalenyl carboxamides as melanin concg. hormone antagonists)

RN 331756-17-3 CAPLUS

CN 3-Pyrrolidinecarboxamide, 5-oxo-1-phenyl-N-[5,6,7,8-tetrahydro-6-(1-piperidinylmethyl)-2-naphthalenyl]- (9CI) (CA INDEX NAME)



AN 1991:157055 CAPLUS
DN **114:157055**
TI L-PGlu-D-Ala-NH2, a peptide analog of piracetam, maintains the plastic properties of synaptic transmission in hippocampal slice preparations during long-term maintenance in vitro
AU Chepkova, A. N.; Doreuli, N. W.; Ostrovskaya, R. U.; Gudasheva, T. A.; Skrebitskii, V. G.
CS All-Union Res. Cent. Mental Health, Moscow, USSR
SO Byulleten Eksperimental'noi Biologii i Meditsiny (1990), 110(12), 602-4
CODEN: BEBMAE; ISSN: 0365-9615
DT Journal
LA Russian
AB Tetanic stimulation of the Schaffer collaterals (SC) in rat hippocampus slices after 6 h in vitro did not produce long-term potentiation (LTP) of the field response amplitude in the CA1 pyramidal cell layer. In contrast, LTP after late tetanization was well preserved in the slices that were perfused for 20 min with 0.5 .mu.M L-pGlu-D-Ala-NH2 (PGAA) after 4-4.5 h in vitro. There were no significant reactivity changes during the perfusion of the slices with this drug concn. Two other drugs with nootropic activity, piracetam (100 .mu.M) and .gamma.-hydroxybutyrate (100 .mu.M, Na salt) did not prevent the disappearance of LTP in the late period in vitro, but enhanced reactivity during the perfusion period. The maintenance of the plastic properties of SC-CA1 synaptic transmission under the influence of PGAA is thought to be the result of some specific interaction of the drug with LTP induction mechanisms. LTP damaged in the late period in vitro might be a new model of memory disturbances and this model may be useful for the comparative estn. of the effectiveness of drugs with proposed nootropic activity and for the anal. of the possible mechanisms of their action.

AN 1996:351172 CAPLUS
DN **125:31527**
TI Cytokine function: A study in biologic diversity
AU Cohen, Marion C.; Cohen, Stanley
CS New Jersey Medical School, UMDNJ, Newark, NJ, 07103-2714, USA
SO American Journal of Clinical Pathology (1996), 105(5), 589-598
CODEN: AJCPAI; ISSN: 0002-9173
PB Lippincott-Raven
DT Journal; General Review
LA English
AB A review with 125 refs. Cytokines are a group of hormone-like polypeptide mediators that play a variety of regulatory roles in both host defense and normal and abnormal homeostatic mechanisms. They may be produced by diverse cell types and exert their function on a variety of cells. Their effects (which may be suppressive or enhancing) are on cellular proliferation, differentiation, activation, and motility. In addn., cytokines can exert cytodestructive effects on infectious agents or tumor cells, either directly or by activating cells with cytodestructive potential. Any given cytokine may have many different biol. effects. However, two different cytokines may have similar or identical activities. Cytokines may be classified on the basis of their cell of origin, their spectrum of activity, the category of activity they influence, the cells that are their targets, or on specific features of their ligand-receptor interaction. The mode of action of many of the cytokines involves typical signal transduction events such as protein phosphorylation, and to date there is only limited understanding of the mechanisms that lead to one activity over another when a specific cytokine is involved in a specific biol. reaction. Nevertheless, elucidation of their role in other pathol. processes has provided insight into autoimmune and allergic diseases, as well as a variety of systemic disorders. Because of their broad spectrum of activity, cytokines have been used in a variety of therapeutic settings involving both infectious diseases and neoplasia. As the no. of known cytokines continues to grow, it will be increasingly difficult for the non-"cytokinologist" to follow the exponentially expanding literature. Hopefully, this brief review will provide an overview that can serve as a framework for the understanding of this important area of biol. and pathol. Cytokines discussed include interferons, tumor necrosis factor, interleukins, chemokines, colony-stimulating factors, and transforming growth factor-.beta..

L2 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2003 ACS
AN 2000:790471 CAPLUS
DN 133:350145
TI Preparation of cyclic amide compounds as chemokine receptor antagonists
IN Ishihara, Yuji; Imamura, Shinichi; Hashiguchi, Shohei; Nishimura, Osamu; Kanzaki, Naoyuki; Baba, Masanori
PA Takeda Chemical Industries, Ltd., Japan
SO PCT Int. Appl., 109 pp.
CODEN: PIXXD2
DT Patent
LA Japanese
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000066551	A1	20001109	WO 2000-JP2765	20000427 <--
	W: AE, AG, AL, AM, AU, AZ, BA, BB, BG, BR, BY, CA, CN, CR, CU, CZ, DM, DZ, EE, GD, GE, HR, HU, ID, IL, IN, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LV, MA, MD, MG, MK, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, TJ, TM, TR, TT, UA, US, UZ, VN, YU, ZA, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	JP 2001011073	A2	20010116	JP 2000-132861	20000427
	EP 1180513	A1	20020220	EP 2000-921055	20000427
	R:/ AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
PRAI	JP 1999-122549	A	19990428		
	WO 2000-JP2765	W	20000427		

OS MARPAT 133:350145
GI



I

AB The title compds. I [R1 is hydrocarbyl and R2 is hydrocarbyl having two or more carbon atoms, or R1 and R2 together with the nitrogen atom adjacent thereto may form a ring which may be substituted; R3 is optionally substituted hydrocarbyl or a heterocyclic group; R4 is hydrogen, hydrocarbyl, a heterocyclic group, or the like; E is a divalent chain hydrocarbon group or the like; G is CO or SO2; J is nitrogen, a methine group, or the like; and Q and R are each a divalent C1-C3 chain hydrocarbon group or the like] are prepd. I exhibit excellent CCR5 antagonism and are useful as preventive or therapeutic drugs for HIV infection of human peripheral blood monocytes, particularly AIDS. In an vitro test for CCR5 antagonism, N-[3-(4-benzyl-1-piperidinyl)propyl]-1-methyl-5-oxo-N-phenyl-3-pyrrolidinecarboxamide hydrochloride at 1 .mu.M gave 57% inhibition of binding of RANTES to the CCR5 receptors. Formulations are given.

RE.CNT 16 THERE ARE 16 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> analyze
ENTER ANSWER SET OR ANALYZE L# OR (L2):l1

```
L1 HAS NO ANSWERS
An L-number has no answers for one of five reasons:
1. It is a query that has not been searched, or
2. It is the result of a search with zero answers, or
3. It is an intermediate result of the ACTIVATE command, or
4. It is an intermediate result in SEARCH STEPS, or
5. It is an L-number created by the RUN command

=> l2
L2 IS NOT A RECOGNIZED COMMAND
The previous command name entered was not recognized by the system.
For a list of commands available to you in the current file, enter
"HELP COMMANDS" at an arrow prompt (=>).

=> analyze
ENTER ANSWER SET OR ANALYZE L# OR (L2):l2
ENTER ANSWER NUMBER OR RANGE (1-):1
ENTER DISPLAY CODE (TI) OR ?:rn
L3          ANALYZE L2 1 RN :     297 TERMS

=> fil reg
COST IN U.S. DOLLARS                              SINCE FILE      TOTAL
                                                     ENTRY    SESSION
FULL ESTIMATED COST                                  17.40      17.61

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)        SINCE FILE      TOTAL
                                                     ENTRY    SESSION
CA SUBSCRIBER PRICE                                  -0.65      -0.65

FILE 'REGISTRY' ENTERED AT 09:29:26 ON 14 APR 2003
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2003 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:   13 APR 2003  HIGHEST RN 502841-39-6
DICTIONARY FILE UPDATES:  13 APR 2003  HIGHEST RN 502841-39-6

TSCA INFORMATION NOW CURRENT THROUGH MAY 20, 2002

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

Crossover limits have been increased.  See HELP CROSSOVER for details.

Experimental and calculated property data are now available.  See HELP
PROPERTIES for more information.  See STNote 27, Searching Properties
in the CAS Registry File, for complete details:
http://www.cas.org/ONLINE/STN/STNOTES/stnotes27.pdf

=> s l3
L4          297 L3

=> s l4 and piperidin?
         587905 PIPERIDIN?
L5          156 L4 AND PIPERIDIN?

=> s l5 and pyrrolidin?
         370358 PYRROLIDIN?
L6           93 L5 AND PYRROLIDIN?
```

=> d scan

L6 93 ANSWERS REGISTRY COPYRIGHT 2003 ACS
IN **3-Pyrrolidinecarboxamide, N-[3-[4-(4-chlorophenyl)-4-hydroxy-1-piperidinyl]propyl]-N-cyclopentyl-1-methyl-5-oxo- (9CI)**
MF C25 H36 Cl N3 O3



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):10

L6 93 ANSWERS REGISTRY COPYRIGHT 2003 ACS
IN **3-Pyrrolidinecarboxamide, N-(2,3-dihydro-1H-inden-5-yl)-1-methyl-5-oxo-N-[3-[4-(phenylmethyl)-1-piperidinyl]propyl]-, monohydrochloride (9CI)**
MF C30 H39 N3 O2 . Cl H



● HCl

L6 93 ANSWERS REGISTRY COPYRIGHT 2003 ACS
IN **3-Pyrrolidinecarboxamide, 5-oxo-N-phenyl-N-[3-[4-(phenylmethyl)-1-piperidinyl]propyl]-1-(2-propynyl)- (9CI)**
MF C29 H35 N3 O2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L6 93 ANSWERS REGISTRY COPYRIGHT 2003 ACS
IN **3-Pyrrolidinecarboxamide, 5-oxo-N,1-diphenyl-N-[3-[4-(phenylmethyl)-1-piperidinyl]propyl]- (9CI)**
MF C32 H37 N3 O2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L6 93 ANSWERS REGISTRY COPYRIGHT 2003 ACS
IN **3-Pyrrolidinecarboxamide, 1-methyl-5-oxo-N-phenyl-N-(3-spiro[1H-indene-1,4'-piperidin]-1'-ylpropyl)-, (2E)-2-butenedioate (1:1) (9CI)**
MF C28 H33 N3 O2 . C4 H4 O4

CM 1



CM 2

Double bond geometry as shown.



L6 93 ANSWERS REGISTRY COPYRIGHT 2003 ACS
IN **3-Pyrrolidinecarboxamide, N-[3-[4-(4-fluorobenzoyl)-1-piperidinyl]-2-hydroxypropyl]-1-methyl-5-oxo-N-phenyl- (9CI)**
MF C27 H32 F N3 O4

PAGE 1-A



PAGE 2-A



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L6 93 ANSWERS REGISTRY COPYRIGHT 2003 ACS
IN **3-Pyrrolidinecarboxamide, N-(4-methoxyphenyl)-1-methyl-5-oxo-N-[3-[4-(phenylmethyl)-1-piperidinyl]propyl]-, monohydrochloride (9CI)**
MF C28 H37 N3 O3 . Cl H



● HCl

L6 93 ANSWERS REGISTRY COPYRIGHT 2003 ACS
IN **3-Pyrrolidinecarboxamide, 1-[(2-fluorophenyl)methyl]-5-oxo-N-phenyl-N-[3-[4-(phenylmethyl)-1-piperidinyl]propyl]- (9CI)**
MF C33 H38 F N3 O2

PAGE 1-A



PAGE 2-A



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L6 93 ANSWERS REGISTRY COPYRIGHT 2003 ACS
IN **3-Pyrrolidinecarboxamide, 1-cyclohexyl-5-oxo-N-phenyl-N-[3-[4-(phenylmethyl)-1-piperidinyl]propyl]- (9CI)**
MF C32 H43 N3 O2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L6 93 ANSWERS REGISTRY COPYRIGHT 2003 ACS
IN **3-Pyrrolidinecarboxamide, N-[3-[4-(hydroxydiphenylmethyl)-1-piperidinyl]propyl]-1-methyl-5-oxo-N-phenyl- (9CI)**
MF C33 H39 N3 O3



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L6 93 ANSWERS REGISTRY COPYRIGHT 2003 ACS
IN **3-Pyrrolidinecarboxamide, N-(1-naphthalenylmethyl)-5-oxo-1-(phenylmethyl)-N-[3-[4-(phenylmethyl)-1-piperidinyl]propyl]- (9CI)**
MF C38 H43 N3 O2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):10

L6 93 ANSWERS REGISTRY COPYRIGHT 2003 ACS
IN **3-Pyrrolidinecarboxamide, N-(3,4-dimethoxyphenyl)-1-methyl-5-oxo-N-[3-[4-(phenylmethyl)-1-piperidinyl]propyl]-, monohydrochloride (9CI)**
MF C29 H39 N3 O4 . Cl H



● HCl

L6 93 ANSWERS REGISTRY COPYRIGHT 2003 ACS
IN **3-Pyrrolidinecarboxamide, 5-oxo-N-phenyl-N-[3-[4-(phenylmethyl)-1-piperidinyl]propyl]-1-(2,2,2-trifluoroethyl)- (9CI)**
MF C28 H34 F3 N3 O2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L6 93 ANSWERS REGISTRY COPYRIGHT 2003 ACS
IN **3-Pyrrolidinecarboxamide, 1-butyl-5-oxo-N-phenyl-N-[3-[4-(phenylmethyl)-1-piperidinyl]propyl]- (9CI)**
MF C30 H41 N3 O2



=> d l1
L1 HAS NO ANSWERS
L1 STR



VAR G1=AK/CB
VAR G2=2/3/4
NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RSPEC 7 4
NUMBER OF NODES IS 17

STEREO ATTRIBUTES: NONE

=> s l1 ful
FULL SEARCH INITIATED 09:37:35 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 40863 TO ITERATE

100.0% PROCESSED 40863 ITERATIONS 16 ANSWERS
SEARCH TIME: 00.00.02

L3 16 SEA SSS FUL L1

=> fil caplus

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	149.75	149.96

FILE 'CAPLUS' ENTERED AT 09:37:40 ON 14 APR 2003
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 14 Apr 2003 VOL 138 ISS 16
FILE LAST UPDATED: 13 Apr 2003 (20030413/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

```
=> s l3
L4            1 L3

=> d bib abs
```

L4 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2003 ACS
AN 2000:790471 CAPLUS
DN 133:350145
TI Preparation of cyclic amide compounds as chemokine receptor antagonists
IN Ishihara, Yuji; Imamura, Shinichi; Hashiguchi, Shohei; Nishimura, Osamu; Kanzaki, Naoyuki; Baba, Masanori
PA Takeda Chemical Industries, Ltd., Japan
SO PCT Int. Appl., 109 pp.
CODEN: PIXXD2
DT Patent
LA Japanese
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000066551	A1	20001109	WO 2000-JP2765	20000427
	W: AE, AG, AL, AM, AU, AZ, BA, BB, BG, BR, BY, CA, CN, CR, CU, CZ, DM, DZ, EE, GD, GE, HR, HU, ID, IL, IN, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LV, MA, MD, MG, MK, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, TJ, TM, TR, TT, UA, US, UZ, VN, YU, ZA, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	JP 2001011073	A2	20010116	JP 2000-132861	20000427
	EP 1180513	A1	20020220	EP 2000-921055	20000427
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
PRAI	JP 1999-122549	A	19990428		
	WO 2000-JP2765	W	20000427		

OS MARPAT 133:350145
GI



I

AB The title compds. I [R1 is hydrocarbyl and R2 is hydrocarbyl having two or more carbon atoms, or R1 and R2 together with the nitrogen atom adjacent thereto may form a ring which may be substituted; R3 is optionally substituted hydrocarbyl or a heterocyclic group; R4 is hydrogen, hydrocarbyl, a heterocyclic group, or the like; E is a divalent chain hydrocarbon group or the like; G is CO or SO2; J is nitrogen, a methine group, or the like; and Q and R are each a divalent C1-C3 chain hydrocarbon group or the like] are prepd. I exhibit excellent CCR5 antagonism and are useful as preventive or therapeutic drugs for HIV infection of human peripheral blood monocytes, particularly AIDS. In an vitro test for CCR5 antagonism, N-[3-(4-benzyl-1-piperidinyl)propyl]-1-methyl-5-oxo-N-phenyl-3-pyrrolidinecarboxamide hydrochloride at 1 .mu.M

gave 57% inhibition of binding of RANTES to the CCR5 receptors. Formulations are given.

RE.CNT 16 THERE ARE 16 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

```
=> d l5
L5 HAS NO ANSWERS
L5                STR
```




```
VAR G1=AK/CB
NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RSPEC   4   7
NUMBER OF NODES IS  16

STEREO ATTRIBUTES: NONE


=> s l5 ful
FULL SEARCH INITIATED 09:38:56 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -  68814 TO ITERATE

100.0% PROCESSED   68814 ITERATIONS                                43 ANSWERS
SEARCH TIME: 00.00.02

L7           43 SEA SSS FUL L5

=> s l7 not l3
L8          27 L7 NOT L3

=> d scan

L8   27 ANSWERS   REGISTRY  COPYRIGHT 2003 ACS
IN   1-Naphthalenecarboxamide, 3-cyano-N-[(2S)-2-(3,4-dichlorophenyl)-4-[4-[2-
     (2-oxo-1-pyrrolidinyl)phenyl]-1-piperidinyl]butyl]-N-methyl-,
     2-hydroxy-1,2,3-propanetricarboxylate (1:1) (9CI)
MF   C38 H38 Cl2 N4 O2 . C6 H8 O7

     CM   1

Absolute stereochemistry.
```



CM 2



HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):26

L8 27 ANSWERS REGISTRY COPYRIGHT 2003 ACS
IN Benzamide, N-[2-(3,4-dichlorophenyl)-4-[4-(2-oxo-1-pyrrolidinyl)-1-piperidinyl]butyl]-N-methyl-, hydrochloride (2:3) (9CI)
MF C27 H33 Cl2 N3 O2 . 3/2 Cl H



●3/2 HCl

L8 27 ANSWERS REGISTRY COPYRIGHT 2003 ACS
IN 2,6-Piperidinedione, 3-(2,5-dihydro-2,5-dioxo-3,4-diphenyl-1H-pyrrol-1-yl)-1-[2-(dimethylamino)ethyl]-, monohydrochloride (9CI)
MF C25 H25 N3 O4 . Cl H



● HCl

L8 27 ANSWERS REGISTRY COPYRIGHT 2003 ACS
IN Benzenesulfonamide, N-methyl-N-[4-[4-(2-oxo-1-pyrrolidinyl)-1-piperidinyl]-2-phenylbutyl]-, monohydrochloride (9CI).
MF C26 H35 N3 O3 S . Cl H



● HCl

L8 27 ANSWERS REGISTRY COPYRIGHT 2003 ACS
IN 1-Pyrrolidinecarboxamide, N-[3-[4-[4-(1,1-dimethylethyl)phenyl]-3,6-dihydro-1(2H)-pyridinyl]propyl]-N-methyl-2-oxo- (9CI)
MF C24 H35 N3 O2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L8 27 ANSWERS REGISTRY COPYRIGHT 2003 ACS
IN 1-Naphthalenecarboxamide, 3-cyano-N-[(2S)-2-(3,4-dichlorophenyl)-4-[4-[2-(2-oxo-1-pyrrolidinyl)phenyl]-1-piperidinyl]butyl]-N-methyl- (9CI)
MF C38 H38 Cl2 N4 O2
CI COM

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L8 27 ANSWERS REGISTRY COPYRIGHT 2003 ACS
IN 1H-Pyrrole-2,5-dione, 3-[1-[1-[3-(dimethylamino)propyl]-4-piperidinyl]-1H-indol-3-yl]-4-(1-methyl-1H-indol-3-yl)- (9CI)
MF C31 H35 N5 O2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L8 27 ANSWERS REGISTRY COPYRIGHT 2003 ACS
IN Benzamide, 4-(2,5-dioxo-1-pyrrolidinyl)-N-[[3-(3-hydroxyphenyl)-1,2,4-oxadiazol-5-yl]methyl]-N-[2-(1-piperidinyl)ethyl]- (9CI)
MF C27 H29 N5 O5



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L8 27 ANSWERS REGISTRY COPYRIGHT 2003 ACS
IN Benzenesulfonamide, N-methyl-N-[4-[4-(2-oxo-1-pyrrolidinyl)-1-piperidinyl]-2-phenylbutyl]- (9CI)
MF C26 H35 N3 O3 S
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L8 27 ANSWERS REGISTRY COPYRIGHT 2003 ACS
IN 1-Pyrrolidinecarboxamide, N-[3-[4-[4-(1,1-dimethylethyl)phenyl]-3,6-dihydro-1(2H)-pyridinyl]propyl]-2-oxo-N-propyl- (9CI)
MF C26 H39 N3 O2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L8 27 ANSWERS REGISTRY COPYRIGHT 2003 ACS
IN 1-Naphthalenecarboxamide, 3-cyano-N-[(2S)-2-(3,4-dichlorophenyl)-4-[4-[2-(2,5-dioxo-1-pyrrolidinyl)phenyl]-1-piperidinyl]butyl]-N-methyl-, 2-hydroxy-1,2,3-propanetricarboxylate (1:1) (9CI)
MF C38 H36 Cl2 N4 O3 . C6 H8 O7

CM 1

Absolute stereochemistry.





CM 2



L8 27 ANSWERS REGISTRY COPYRIGHT 2003 ACS
IN Carbamic acid, [1-(cyclohexylmethyl)-2-[2-[[(2,5-dioxo-1-pyrrolidinyl)oxy]carbonyl]-1-piperidinyl]-2-oxoethyl]methyl-, 1,1-dimethylethyl ester, [S-(R*,S*)]- (9CI)
MF C25 H39 N3 O7

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L8 27 ANSWERS REGISTRY COPYRIGHT 2003 ACS
IN Benzamide, 4-(2,5-dioxo-1-pyrrolidinyl)-N-[[3-(4'-hydroxy[1,1'-biphenyl]-4-yl)-1,2,4-oxadiazol-5-yl]methyl]-N-[2-(1-piperidinyl)ethyl]- (9CI)
MF C33 H33 N5 O5



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L8 27 ANSWERS REGISTRY COPYRIGHT 2003 ACS
IN 1-Piperidinepentanamide, .alpha.-(3,4-dichlorophenyl)-N-methyl-4-(2-oxo-1-pyrrolidinyl)-N-(phenylmethyl)-, ethanedioate (1:1) (9CI)
MF C28 H35 Cl2 N3 O2 . C2 H2 O4

CM 1



CM 2



L8 27 ANSWERS REGISTRY COPYRIGHT 2003 ACS
IN 2-Pyrrolidinone, 1-[4-methoxy-2-nitro-5-(1-piperidinyl)phenyl]- (9CI)
MF C16 H21 N3 O4



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L8 27 ANSWERS REGISTRY COPYRIGHT 2003 ACS
IN 1-Naphthalenecarboxamide, 3-cyano-N-[(2S)-2-(3,4-dichlorophenyl)-4-[4-[2-(2,5-dioxo-1-pyrrolidinyl)phenyl]-1-piperidinyl]butyl]-N-methyl- (9CI)
MF C38 H36 Cl2 N4 O3
CI COM

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L8 27 ANSWERS REGISTRY COPYRIGHT 2003 ACS
IN 1-Pyrrolidinecarboxamide, N-[3-[4-[4-(1,1-dimethylethyl)phenyl]-4-hydroxy-1-piperidinyl]propyl]-2-oxo-N-propyl- (9CI)
MF C26 H41 N3 O3



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L8 27 ANSWERS REGISTRY COPYRIGHT 2003 ACS
IN Benzamide, 4-(2,5-dioxo-1-pyrrolidinyl)-N-[[3-(4-hydroxyphenyl)-1,2,4-oxadiazol-5-yl]methyl]-N-[2-(1-piperidinyl)ethyl]- (9CI)
MF C27 H29 N5 O5



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L8 27 ANSWERS REGISTRY COPYRIGHT 2003 ACS
IN 1-Piperidinepentanamide, .alpha.-(3,4-dichlorophenyl)-N-methyl-4-(2-oxo-1-pyrrolidinyl)-N-(phenylmethyl)- (9CI)
MF C28 H35 Cl2 N3 O2
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L8 27 ANSWERS REGISTRY COPYRIGHT 2003 ACS
IN 2,6-Piperidinedione, 1,1'-[(methylimino)di-2,1-ethanediyl]bis[3-(2,5-dihydro-2,5-dioxo-3,4-diphenyl-1H-pyrrol-1-yl)- (9CI)
MF C47 H41 N5 O8



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L8 27 ANSWERS REGISTRY COPYRIGHT 2003 ACS
IN 4-Piperidineacetamide, .alpha.-[3-amino-3-[4-[(2,6-dimethyl-4-pyridinyl)methoxy]phenyl]-2-oxo-1-pyrrolidinyl]-1-[(dimethylamino)carbonyl]-N-hydroxy-, (.alpha.R)-, mono(trifluoroacetate) (salt) (9CI)
MF C28 H38 N6 O5 . C2 H F3 O2

CM 1

Absolute stereochemistry.



CM 2



L8 27 ANSWERS REGISTRY COPYRIGHT 2003 ACS
IN 1-Pyrrolidinecarboxamide, N-[3-(4-[1,1'-biphenyl]-4-yl-3,6-dihydro-1(2H)-pyridinyl)propyl]-N-methyl-2-oxo-, ethanedioate (1:1) (9CI)
MF C26 H31 N3 O2 . C2 H2 O4

CM 1



CM 2



L8 27 ANSWERS REGISTRY COPYRIGHT 2003 ACS
IN Benzamide, 4-(2,5-dioxo-1-pyrrolidinyl)-N-[[3-(2-fluoro-4-hydroxyphenyl)-1,2,4-oxadiazol-5-yl]methyl]-N-[2-(1-piperidinyl)ethyl]- (9CI)
MF C27 H28 F N5 O5



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L8 27 ANSWERS REGISTRY COPYRIGHT 2003 ACS
IN Benzamide, N-[2-(3,4-dichlorophenyl)-4-[4-(2-oxo-1-pyrrolidinyl)-1-piperidinyl]butyl]-N-methyl- (9CI)
MF C27 H33 Cl2 N3 O2
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L8 27 ANSWERS REGISTRY COPYRIGHT 2003 ACS
IN 2,6-Piperidinedione, 3-(2,5-dihydro-2,5-dioxo-3,4-diphenyl-1H-pyrrol-1-yl)-1-[2-(dimethylamino)ethyl]- (9CI)
MF C25 H25 N3 O4
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L8 27 ANSWERS REGISTRY COPYRIGHT 2003 ACS
IN 4-Piperidineacetamide, .alpha.-[3-amino-3-[4-[(2,6-dimethyl-4-pyridinyl)methoxy]phenyl]-2-oxo-1-pyrrolidinyl]-1-[(dimethylamino)carbonyl]-N-hydroxy-, (.alpha.R)- (9CI)
MF C28 H38 N6 O5
CI COM

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L8 27 ANSWERS REGISTRY COPYRIGHT 2003 ACS
IN 1-Pyrrolidinecarboxamide, N-[3-(4-[1,1'-biphenyl]-4-yl-3,6-dihydro-1(2H)-pyridinyl)propyl]-N-methyl-2-oxo- (9CI)
MF C26 H31 N3 O2
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

ALL ANSWERS HAVE BEEN SCANNED

AN 1991:164815 CAPLUS
DN 114:164815
TI Preparation of peptides as antidementia agents
IN Masaki, Mitsuo; Uehara, Masaki; Hirate, Kenji; Isowa, Yoshikazu; Sato, Yoshiaki; Nakashima, Yoshiharu
PA Nippon Chemiphar Co., Ltd., Japan; Fujirebio, Inc.
SO Eur. Pat. Appl., 36 pp.
CODEN: EPXXDW
DT Patent
LA English
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 393934	A1	19901024	EP 1990-303987	19900412
	EP 393934	B1	19941102		
	R: AT, BE, CH, DE, DK, FR, GB, IT, LI, NL, SE				
	JP 02273694	A2	19901108	JP 1989-95920	19890415
	JP 08026067	B4	19960313		
	JP 02273696	A2	19901108	JP 1989-95917	19890415
	JP 2640778	B2	19970813		
	JP 02273695	A2	19901108	JP 1989-95918	19890415
	JP 2542254	B2	19961009		
	JP 02273697	A2	19901108	JP 1989-95919	19890415
	JP 08032722	B4	19960329		
	JP 02273698	A2	19901108	JP 1989-95921	19890415
	JP 08026069	B4	19960313		
	JP 02273699	A2	19901108	JP 1989-95922	19890415
	JP 08026070	B4	19960313		
	CA 2014590	AA	19901015	CA 1990-2014590	19900412
	EP 620230	A1	19941019	EP 1994-100233	19900412
	R: AT, BE, CH, DE, DK, FR, GB, IT, LI, NL, SE				
	US 5112947	A	19920512	US 1990-509950	19900416
	AU 9053621	A1	19901018	AU 1990-53621	19900417
	AU 642644	B2	19931028		
	ZA 9002869	A	19910227	ZA 1990-2869	19900417
	US 5349050	A	19940920	US 1992-838140	19920218

PRAI JP 1989-95917 19890415
JP 1989-95918 19890415
JP 1989-95919 19890415
JP 1989-95920 19890415
JP 1989-95921 19890415
JP 1989-95922 19890415
EP 1990-303987 19900412
US 1990-509950 19900416

OS MARPAT 114:164815

GI



I

AB The title peptides [I; A = D- or L-Pro and B = citrulline (Cit) or homoarginine (Har) residue; A = D-Pro, B = Arg; A = Sar, pipecolic acid residue (Pip), azetidine-2-carboxylic acid (Aze), or Arg, B = D- or L-Arg], H-Asn-A-L- (or D-) Pro-Arg-(Gly)nOH (A = Ser, Thr, Ala; n = 0, 1), A-Ser-Pip-Arg-OH (A = H-Pro-Asn, H-Asn, H-Pro), A-Cys(W)-Pro-Arg-B [A = cyclopentylcarbonyl, H-Pro, H-pGlu (pGlu = pyroglutamic acid residue); B = Gly-OH, .beta.-Ala-OH; W = H, S-linked H-Cys-OH or (A-Cys-Pro-Arg-B)2], H-pGlu-Asn-Ser-A-B-(Gly)nOH (A = Aze, D- or L-Pro, Pip, Ser; B = D- or

L-Arg, Cit, Har, Lys, Orn; n = 0, 1), H-Pro-(Asn)m-Ser-L-(or D-)-Pro-Arg-(Gly)nOH (m, n = 0, 1), and H-Pro-(Asn)m-Ser-L-(or D-)-Pro-Arg-(Gly)nOH (n = 0, 1), having a nootropic effect superior to vasopressin, were prepd. Approx. 30 peptides were prepd. by the soln. method and 8 peptides at 0.1 and 1 ng/kg showed 213-460% improvement effect on memory consolidation in retrograde amnesia induced by a electro-shock and cycloheximide. Injection, collunarium, and suppository formulations contg. the title peptides are given.

IT **132925-83-8DP**, 2,4-dimethoxybenzhydrylamine resin-bound
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. and peptide coupling with, in prepn. of antidementia peptide)

RN 132925-83-8 CAPLUS

CN Glycinamide, 5-oxo-L-prolyl-L-asparaginyl-S-(triphenylmethyl)-L-cysteinyl-(2S)-2-piperidinecarbonyl-N5-[imino[[(4-methoxy-2,3,6-trimethylphenyl)sulfonyl]amino]methyl]-L-ornithyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



AN 2000:314542 CAPLUS
DN 132:308252
TI Preparation of dihydropyridinones and pyrrolinones useful as alpha 1a adrenoceptor antagonists
IN Barrow, James; Selnick, Harold G.; Nanterment, Philippe G.
PA Merck & Co., Inc., USA
SO PCT Int. Appl., 112 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000025782	A1	20000511	WO 1999-US24990	19991025
	W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	US 6235759	B1	20010522	US 1999-428973	19991028
PRAI	US 1998-106095P	P	19981029		
	US 1999-141463P	P	19990629		

OS MARPAT 132:308252
GI



I



II

AB Novel dihydropyridinone and pyrrolinone compds. [I; Y = CH or N; X = CR4R5, when Y = N; X = NR6, when Y = CH; R1 = Ph, mono- or poly-substituted Ph, naphthyl, mono- or poly-substituted naphthyl, heterocyclic, or mono- or poly-substituted heterocyclic; wherein the heterocyclic is selected from the group consisting of pyridyl, pyrazinyl,

thienyl, thiazolyl, furanyl and quinazolinyl; R2 = H, cyano, hydroxy, C1-6 alkoxy, CO2Rc, C(O)N(Rc)2, tetrazole, isooxadiazole, Ph, mono- or poly-substituted Ph, naphthyl, mono- or poly-substituted naphthyl, heterocyclic, or mono- or poly-substituted heterocyclic; wherein the heterocyclic is selected from the group consisting of pyridyl, thienyl and furanyl; R3 = a substituent connected to a ring atom other than CR1R2 or Y which is independently C1-4 alkyl; R4, R5 = H, C1-6 alkyl, C3-8 cycloalkyl; R6 = H, C1-4 alkyl; R7 = Ph, or mono- or poly-substituted phenyl; R8 = H, C1-6 alkyl, (CH2)0-4CO2Rc, (CH2)0-4C(O)Rc; R9 = H, halo, cyano, C1-6 alkyl, C3-8 cycloalkyl, C1-6 alkoxy, halogenated C1-6 alkyl, halogenated C3-8 cycloalkyl, halogenated C1-6 alkoxy, (CH2)1-4ORb, CO2Rc, C(O)Rc, or C(O)N(Rc)2; Rb, Rc = H, C1-6 alkyl, halogenated C1-6 alkyl; m = 0-2; n = 2-4, when X = NR6; n = 1-3, when X = CR4R5; p1 = 0 or 1, provided that when Y = N, p1 = 0; p, q = 0-2, p+q.ltoreq.3] or pharmaceutically acceptable salts thereof are prepd. Their use as alpha 1a adrenergic receptor antagonists is also described (no data). One application of these compds. is in the treatment of benign prostatic hyperplasia. These compds. are selective in their ability to relax smooth muscle tissue enriched in the alpha 1a receptor subtype without at the same time inducing hypotension. One such tissue is found surrounding the urethral lining. Therefore, one utility of the instant compds. is to provide acute relief to males suffering from benign prostatic hyperplasia, by permitting less hindered urine flow. Another utility of the instant compds. is provided by combination with a human 5-alpha reductase inhibitory compd., such that both acute and chronic relief from the effects of benign prostatic hyperplasia can be achieved. Thus, 3-[4-(2-pyridyl)piperidin-1-yl]propylamine was condensed with (R)-(-)-4-(3,4-difluorophenyl)-6-methyl-3,4-dihydro-2-pyridinone-5-carboxylic using 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride, 1-hydroxy-7-azabenenetriazole, and Et3N in DMF to give title compd. (II).

IT **266318-52-9P 266318-53-0P 266318-55-2P**

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of dihydropyridinones and pyrrolinones useful as alpha 1a adrenoceptor antagonists for treatment of benign prostatic hyperplasia)

RN 266318-52-9 CAPLUS

CN 3-Pyridinecarboxamide, N-[2-[[trans-4-(2-cyanophenyl)cyclohexyl]amino]ethyl]-4-(3,4-difluorophenyl)-1,4,5,6-tetrahydro-2-methyl-6-oxo-, (4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 266318-53-0 CAPLUS

CN 3-Pyridinecarboxamide, N-[2-[[trans-4-(2-cyanophenyl)cyclohexyl]amino]ethyl]-4-(3,4-difluorophenyl)-1,4,5,6-tetrahydro-2-methyl-6-oxo-, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 266318-55-2 CAPLUS
CN 3-Pyridinecarboxamide, N-[2-[[trans-4-(2-cyanophenyl)cyclohexyl]amino]ethyl]-4-(3,4-difluorophenyl)-1,4,5,6-tetrahydro-1,2-dimethyl-6-oxo-, (4R)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

AN 1986:442838 CAPLUS
DN 105:42838
TI Substituted pyrrolidinones and their use in treating reduced cerebral function
IN Weber, Karl Heinz; Schneider, Claus; Walther, Gerhard; Hinzen, Dieter; Kuhn, Franz Josef; Lehr, Erich; Ensinger, Helmut; Troeger, Wolfgang
PA Boehringer Ingelheim K.-G., Fed. Rep. Ger.
SO Ger. Offen., 27 pp.
CODEN: GWXXBX
DT Patent
LA German
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	DE 3420193	A1	19851205	DE 1984-3420193	19840530
	EP 163260	A1	19851204	EP 1985-106343	19850523
	EP 163260	B1	19880803		
	R: AT, BE, CH, DE, FR, GB, IT, LI, LU, NL, SE				
	AT 36151	E	19880815	AT 1985-106343	19850523
	US 4670456	A	19870602	US 1985-738152	19850524
	PL 144921	B1	19880730	PL 1985-253668	19850528
	FI 8502130	A	19851201	FI 1985-2130	19850529
	FI 78462	B	19890428		
	FI 78462	C	19890810		
	DK 8502396	A	19851201	DK 1985-2396	19850529
	NO 8502133	A	19851202	NO 1985-2133	19850529
	HU 37751	A2	19860228	HU 1985-2056	19850529
	HU 193393	B	19870928		
	DD 235256	A5	19860430	DD 1985-276752	19850529
	ES 543592	A1	19860601	ES 1985-543592	19850529
	ZA 8504072	A	19870225	ZA 1985-4072	19850529
	SU 1360583	A3	19871215	SU 1985-3900955	19850529
	IL 75339	A1	19880731	IL 1985-75339	19850529
	CS 261883	B2	19890210	CS 1985-3854	19850529
	CA 1255664	A1	19890613	CA 1985-482660	19850529
	AU 8543170	A1	19851205	AU 1985-43170	19850530
	AU 581438	B2	19890223		
	JP 61000068	A2	19860106	JP 1985-117657	19850530
	JP 05017904	B4	19930310		
	ES 552410	A1	19870901	ES 1986-552410	19860226
	ES 552411	A1	19870901	ES 1986-552411	19860226
	ES 552409	A1	19871216	ES 1986-552409	19860226
	US 4762832	A	19880809	US 1986-943532	19861218
	US 4857528	A	19890815	US 1988-183819	19880420
	US 4891378	A	19900102	US 1989-365169	19890612
PRAI	DE 1984-3420193		19840530		
	EP 1985-106343		19850523		
	US 1985-738152		19850524		
	US 1986-943532		19861218		
	US 1988-183819		19880420		

OS CASREACT 105:42838
GI



I



II



I



II

AB Pyrrolidinones I [R1 = pyridyl, (un)substituted Ph; R2 = H, alkyl; R3 = alkyl, hydroxyalkyl, Ph (un)substituted by Cl, Br, Me, or MeO, cyclohexyl, dialkylaminoalkyl; R4 = H, alkyl; R3R4N = piperidino, morpholino, or piperazine (un)substituted by Me, piperazine 4-substituted by Ph, ClC6H4, or PhCH2 nortropanyl] and their physiol. tolerable acid addn. salts, useful as brain-protective agents at 100 mg/kg orally (hypoxia tolerance test), were prepd by 4 methods. 4-Aminoethyl-1-benzyl-2-pyrrolidinone in dioxane was treated with chlorocarbonylmethylpiperazine and the product treated with 2N NaOH to alky. to give 70% II. Pharmaceutical formulations contg. I were given.

IT **103296-08-8P 103296-26-0P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of, for cerebral insufficiency treatment)

RN 103296-08-8 CAPLUS

CN 1-Piperazinecarboxamide, N,4-dimethyl-N-[[5-oxo-1-(phenylmethyl)-3-pyrrolidinyl]methyl]- (9CI) (CA INDEX NAME)



RN 103296-26-0 CAPLUS

CN 1-Piperidinecarboxamide, N-[[5-oxo-1-(phenylmethyl)-3-pyrrolidinyl]methyl]- (9CI) (CA INDEX NAME)


O
CH2 — Ph
N
CH2
NH
C
O
N

AN 2001:265385 CAPLUS
DN 134:295739
TI Preparation of N-aryl-N-(heterocyclylalkyl)piperidinecarboxamides as CCR5 antagonists
IN Imamura, Shinichi; Hashiguchi, Shohei; Hattori, Taeko; Nishimura, Osamu; Kanzaki, Naoyuki; Baba, Masanori; Sugihara, Yoshihiro
PA Takeda Chemical Industries, Ltd., Japan
SO PCT Int. Appl., 392 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001025200	A1	20010412	WO 2000-JP6755	20000929
	W: AE, AG, AL, AM, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CN, CR, CU, CZ, DM, DZ, EE, GD, GE, HR, HU, ID, IL, IN, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LV, MA, MD, MG, MK, MN, MX, MZ, NO, NZ, PL, RO, RU, SG, SI, SK, TJ, TM, TR, TT, UA, US, UZ, VN, YU, ZA, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	JP 2001302633	A2	20011031	JP 2000-302841	20000929
	BR 2000014428	A	20020611	BR 2000-14428	20000929
	EP 1220842	A1	20020710	EP 2000-962967	20000929
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				
	JP 2003048880	A2	20030221	JP 2002-180545	20000929
	NO 2002001450	A	20020603	NO 2002-1450	20020322
PRAI	JP 1999-282088	A	19991001		
	JP 2000-46749	A	20000218		
	JP 2000-302841	A3	20000929		
	WO 2000-JP6755	W	20000929		

OS MARPAT 134:295739
RE.CNT 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L2 ANSWER 8 OF 10 CAPLUS COPYRIGHT 2003 ACS
AN 2001:83685 CAPLUS
DN 134:289960
TI Antagonists of the human CCR5 receptor as anti-HIV-1 agents. Part 2: Structure-activity relationships for substituted 2-aryl-1-[N-(**methyl**)-N-(phenylsulfonyl)amino]-4-(**piperidin**-1-yl)butanes
AU Finke, P. E.; Meurer, L. C.; Oates, B.; Mills, S. G.; MacCoss, M.; Malkowitz, L.; Springer, M. S.; Daugherty, B. L.; Gould, S. L.; DeMartino, J. A.; Siciliano, S. J.; Carella, A.; Carver, G.; Holmes, K.; Danzeisen, R.; Hazuda, D.; Kessler, J.; Lineberger, J.; Miller, M.; Schleif, W. A.; Emini, E. A.
CS Department of Medicinal Chemistry, Merck Research Laboratories, Rahway, NJ, 07065, USA
SO Bioorganic & Medicinal Chemistry Letters (2001), 11(2), 265-270
CODEN: BMCLE8; ISSN: 0960-894X
PB Elsevier Science Ltd.
DT Journal
LA English
RE.CNT 23 THERE ARE 23 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

IT 3446-75-1P, 4-(Ethylthio)benzyl chloride 10575-41-4P, Hex-4-yn-3-one 20739-59-7P, Hex-4-yn-3-ol 37088-66-7P, Methyl (3S)-3-amino-3-phenylpropionate 123855-51-6P, 1-(tert-Butoxycarbonyl)-4-hydroxymethylpiperidine 135865-78-0P, tert-Butyl (1S)-3-oxo-1-phenylpropylcarbamate 137076-22-3P, 1-(tert-Butoxycarbonyl)-4-formylpiperidine 139290-70-3P, 1-(tert-Butoxycarbonyl)**piperidine**-4-**N-methyl**-N-methoxycarboxamide 142374-19-4P, N-tert-Butoxycarbonyl-4-piperidylacetaldehyde 190189-97-0P, Methyl (3S)-3-[(tert-butoxycarbonyl)amino]-3-phenylpropionate 203664-61-3P,

AN 2002:965134 CAPLUS
DN 138:39281
TI Preparation of 4-pyrazolylpiperidines and other heterocycles as modulators of CCR5 chemokine receptor activity useful against AIDS
IN Kim, Ronald M.; Chang, Jiang; Chapman, Kevin T.; Mills, Sander G.
PA USA
SO U.S. Pat. Appl. Publ., 70 pp.
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2002193407	A1	20021219	US 2001-973920	20011010
	US 6511994	B2	20030128		
PRAI	US 2000-239285P	P	20001011		

OS MARPAT 138:39281
GI



AB 4-Pyrazolylpiperidines and other heterocycles (QCH2CH2CR3R4NR2XR1; Q shown as I-III with connection by N; variables described below; e.g. N-[(1S)-1-phenyl-3-[4-[3-benzyl-1-ethyl-1H-pyrazol-5-yl]piperidin-1-yl]propyl]cyclobutanecarboxamide bis(trifluoroacetate)) are claimed. The compds. are modulators of CCR5 chemokine receptor activity (no data). The compds. are useful, for example, in the prevention or treatment of infection by HIV (no data) and the treatment of AIDS (no data), as compds. or pharmaceutically acceptable salts, or as ingredients in pharmaceutical compns., optionally in combination with other antivirals, immunomodulators, antibiotics or vaccines. Methods of treating AIDS and methods of preventing or treating infection by HIV are also described. For the claimed compds.: R1 is C1-8alkyl, C2-8alkenyl, C2-8alkynyl, C3-8cycloalkyl, C5-8cycloalkenyl, -O-C3-8cycloalkyl, -NRaRb, Ph, naphthyl, or heterocycle; X is a direct single bond, -C(:O)-, -C(:O)O-, -C(:O)N(Re)-, -SO2-, or -C(:O)N(Re)SO2-; R2 is H or C1-8alkyl; or alternatively R1 and R2 together with the N to which R2 is attached and the X, as defined above, to which R1 is attached, form a 4- to 8-membered monocyclic ring contg. 1-3 N atoms, 0-2 O atoms, and 0-2 S atoms. R3 is H, -CO-NRcRd, or C1-4alkyl; R4 is Ph, naphthyl, or heterocycle; R5 is: H, C1-6alkyl, cyano, -OH, or halo; Y is: a direct single bond, -C1-10alkyl or -(C0-6 alkyl)C3-6cycloalkyl(C0-6alkyl)-, -(C0-6alkyl)-Z1-(C0-6alkyl)- (Z1 = -SO2-, -N(Rf)-, -N(Rf)C(:CHRu)N(Rf)-, -N(Rf)C(:NRu)N(Rf)-, -S-, -O-, -SO-, -SO2N(Rf)-, -N(Rf)SO2-, and -PO2-); -(C0-6alkyl)-Z2-(C0-6alkyl)- (Z2 = -C(:O)-, -C(:O)O-, -OC(:O)-, -C(:O)NRg-, -NRgC(:O)-, -OC(:O)NRg-, -NRgC(:O)O-, and -NRhC(:O)NRg-). R6 is Ph, naphthyl, indanyl, tetrahydronaphthyl, biphenyl, or heterocycle; each R7 = halo, cyano, -OH, -O-C1-6alkyl, -C3-6 cycloalkyl, -CO2H, -CO2-(C1-6alkyl), -CF3, -SO2Rs, -NRsRt, Ph, naphthyl, biphenyl, or heterocycle; each R8 = halo, cyano, -OH, C1-6alkyl, C1-6 haloalkyl, -O-C1-6alkyl, -O-C1-6haloalkyl, -CO2H, -CO2(C1-6alkyl), -NRsRt, -(C1-6alkyl)-NRsRt, -SO2Rs-N(Rs)SO2Rt, -N(Rs)CORt, -(C1-6alkyl)-OH, -O-C3-6 cycloalkyl, benzyloxy, phenoxy, or

-NO2. Each of Ra and Rb = C1-6alkyl; each Rc = H or C1-4alkyl; each Rd = H or C1-4alkyl; Re is H or C1-4alkyl; Rf is H, C1-6alkyl, C2-6alkenyl, benzyl, Ph, (CO)C1-6alkyl, -SO2-C1-6alkyl, -SO2-Ph, -SO2-heterocyclyl, or C1-6 alkyl-C3-6cycloalkyl; Rg is H, C1-6alkyl, C2-6 alkenyl, C2-6alkynyl, benzyl, Ph, or C1-6 alkyl-C3-6cycloalkyl; ; Rh is H or C1-6alkyl; each Rs = H, C1-6alkyl, C5-6 cycloalkyl, benzyl or phenyl; each Rt = H, C1-6 alkyl, C5-6cycloalkyl, benzyl or phenyl; Ru is H, C1-4alkyl, -NO2 or -CN. Each p = 0-2; and with the proviso that when Q is I and Y is a direct single bond, then R6 is Ph, naphthyl, indanyl, tetrahydronaphthyl, biphenyl, or a heterocycle = pyrazolyl and tetrahydropyridopyrazolyl. Addnl. details are given in the claims. Although the methods of prepn. are not claimed, 78 example prepns. are included.

IT **478409-04-0P**, N-[(1S)-1-Phenyl-3-[4-[3-benzyl-1-ethyl-1H-pyrazol-5-yl]piperidin-1-yl]propyl](5-oxopyrrolidin-3-yl)acetamide
RL: CPN (Combinatorial preparation); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); CMBI (Combinatorial study); PREP (Preparation); USES (Uses)
(drug candidate; prepn. of 4-pyrazolylpiperidines and other heterocycles as modulators of CCR5 chemokine receptor activity useful against AIDS)

RN 478409-04-0 CAPLUS

CN 3-Pyrrolidineacetamide, N-[(1S)-3-[4-[1-ethyl-3-(phenylmethyl)-1H-pyrazol-5-yl]-1-piperidinyl]-1-phenylpropyl]-5-oxo- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



AN 1992:83543 CAPLUS
DN 116:83543
TI Preparation of 4-aryl-1,2,5,6-tetrahydropyridine as psychotropic agents
IN Matsumura, Hiromu; Yano, Toshisada; Hashizume, Hiroshi; Matsushita, Akira; Eigyo, Masami
PA Shionogi and Co., Ltd., Japan
SO Eur. Pat. Appl., 79 pp.
CODEN: EPXXDW
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 445701	A1	19910911	EP 1991-103232	19910304
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE				
	US 5149817	A	19920922	US 1991-655585	19910215
	JP 04211059	A2	19920803	JP 1991-47656	19910219
	AU 9172038	A1	19910905	AU 1991-72038	19910301
	AU 643258	B2	19931111		
	EP 861832	A1	19980902	EP 1998-107715	19910304
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE				
	CA 2037566	AA	19910906	CA 1991-2037566	19910305
	US 5243051	A	19930907	US 1992-903924	19920626
	US 5362873	A	19941108	US 1993-76163	19930614
	US 5410058	A	19950425	US 1994-202554	19940228
PRAI	JP 1990-54220		19900305		
	US 1991-655585		19910215		
	EP 1991-103232		19910304		
	US 1992-903924		19920626		
	US 1993-76163		19930614		

OS MARPAT 116:83543
GI



I



II

AB The title compds. [I; Ar = (un)substituted Ph, thienyl; R = OH, R2R3N(CO)p(NR1)q, (un)substituted PH, PhNH, PhO; R1-R3 = H, alkyl; NR2R3 = heterocyclyl; n = 2-6; p, q = 0, 1 (q = 1 .noteq. p)] were prepd. Thus, phenylhydroxypiperidine II (prepn. given) was condensed with Cl(CH2)3Br and the product condensed with morpholine to give, after dehydration, I (Ar = 4-Me3CC6H4, R = morpholino, n = 3). II (Ar = 4-Me3CC6H4, R = Me, n = 3) had Ki of 3.1 .times. 10-4 .mu.M for binding at rat **cerebral** cortex .sigma. receptors in vitro.

IT **137884-73-2P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. and reaction of, in prepn. of psychotropic agents)

RN 137884-73-2 CAPLUS
CN 1-Pyrrolidinecarboxamide, N-[3-[4-[4-(1,1-dimethylethyl)phenyl]-4-hydroxy-1-piperidinyl]propyl]-2-oxo-N-propyl- (9CI) (CA INDEX NAME)



IT **137883-36-4P 137883-56-8P 137883-58-0P**
137883-61-5P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of, as psychotropic agent)
RN 137883-36-4 CAPLUS
CN 1-Pyrrolidinecarboxamide, N-[3-[4-[4-(1,1-dimethylethyl)phenyl]-3,6-dihydro-1(2H)-pyridinyl]propyl]-2-oxo-N-propyl- (9CI) (CA INDEX NAME)



RN 137883-56-8 CAPLUS
CN 1-Pyrrolidinecarboxamide, N-[3-[4-[4-(1,1-dimethylethyl)phenyl]-3,6-dihydro-1(2H)-pyridinyl]propyl]-N-methyl-2-oxo- (9CI) (CA INDEX NAME)



RN 137883-58-0 CAPLUS
CN 1-Pyrrolidinecarboxamide, N-[3-(4-[1,1'-biphenyl]-4-yl-3,6-dihydro-1(2H)-pyridinyl)propyl]-N-methyl-2-oxo- (9CI) (CA INDEX NAME)



RN 137883-61-5 CAPLUS
CN 1-Pyrrolidinecarboxamide, N-[3-(4-[1,1'-biphenyl]-4-yl-3,6-dihydro-1(2H)-pyridinyl)propyl]-N-methyl-2-oxo-, ethanedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 137883-58-0
CMF C26 H31 N3 O2



CM 2

CRN 144-62-7
CMF C2 H2 O4



AN 1966:104044 CAPLUS
DN 64:104044
OREF 64:19549f
TI Basic 2-piperidinones as potential central nervous depressants and anticholinergics
AU Bishop, D. C.; Cavalla, J. F.
CS Parke, Davis Co., Hounslow, UK
SO J. Chem. Soc., C, Org. (1966), (9), 802-5
DT Journal
LA English
AB 3-Dimethylamino-3-phenyl- and 5-dimethylamino-5-phenyl-2-piperidinone and their N-methyl derivs. were synthesized as potential central nervous depressants related to the corresponding potent aminophenylcyclohexanes. Some diethylaminoalkylamides of the intermediates 2-piperidinone 3- and 6-esters were prepd. as possible anticholinergics.
IT **5632-71-3**, Nipecotamide, N-[2-(diethylamino)ethyl]-6-oxo-3-phenyl-
5632-74-6, Nipecotamide, N-[3-(diethylamino)propyl]-6-oxo-3-phenyl-
5667-33-4, Nipecotamide, N-[2-(diethylamino)ethyl]-6-oxo-3-phenyl-, tartrate (1:1)
(prepn. of)
RN 5632-71-3 CAPLUS
CN Nipecotamide, N-[2-(diethylamino)ethyl]-6-oxo-3-phenyl- (7CI, 8CI) (CA INDEX NAME)



RN 5632-74-6 CAPLUS
CN Nipecotamide, N-[3-(diethylamino)propyl]-6-oxo-3-phenyl- (7CI, 8CI) (CA INDEX NAME)



RN 5667-33-4 CAPLUS
CN Nipecotamide, N-[2-(diethylamino)ethyl]-6-oxo-3-phenyl-, tartrate (1:1) (8CI) (CA INDEX NAME)

CM 1

CRN 47255-76-5
CMF C18 H27 N3 O2

Rotation (+).



CM 2

CRN 87-69-4
CMF C4 H6 O6

Absolute stereochemistry.



=> d l1
L1 HAS NO ANSWERS
L1 STR



VAR G1=C/S
VAR G2=AK/CB
NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RSPEC 4 7
NUMBER OF NODES IS 15

STEREO ATTRIBUTES: NONE

=> s l1 ful
FULL SEARCH INITIATED 13:07:41 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 1215 TO ITERATE

100.0% PROCESSED 1215 ITERATIONS 109 ANSWERS
SEARCH TIME: 00.00.01

L3 109 SEA SSS FUL L1

=> fil caplus

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	149.75	149.96

FILE 'CAPLUS' ENTERED AT 13:07:45 ON 11 APR 2003
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 11 Apr 2003 VOL 138 ISS 16
FILE LAST UPDATED: 10 Apr 2003 (20030410/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s l3
L4 3 L3

=> d bib abs 1-3

L4 ANSWER 1 OF 3 CAPLUS COPYRIGHT 2003 ACS
AN 2002:777885 CAPLUS
DN 137:295252
TI Preparation of peptides for pharmaceutical use as modulators of melanocortin receptors
IN Yu, Guixue; Macor, John; Herpin, Timothy; Lawrence, R. Michael; Morton, George C.; Ruel, Rejean; Poindexter, Graham S.; Ruediger, Edward H.; Thibault, Carl
PA Bristol-Myers Squibb Company, USA
SO PCT Int. Appl., 116 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 3

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002079146	A2	20021010	WO 2002-US6581	20020302
WO 2002079146	A3	20030206		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRAI US 2001-273206P P 20010302
US 2001-273291P P 20010302
OS MARPAT 137:295252
GI



I

AB Compds. W-(CH2)y(CR4R5)xCO-X(R1)CHR2(CHR3)r(CH2)sCO-E [X = N or CH; R1, R3 = H or alkyl; R2 = H, aryl, cycloalkyl, heteroaryl, heterocyclyl, (un)substituted alkyl or alkenyl; R1 together with R2 or R3 or R2 together

with R3 form mono- or bicyclic aryl, cycloalkyl, heteroaryl, or heterocyclyl; E = (un)substituted pyrrolidino, piperidino, or hexahydro-1-azepinyl; R4, R5 = H, (un)substituted alkyl, halo, hydroxy, amino, aryl, cycloalkyl, heterocyclyl, spirocycloalkyl ring; r, s = 0 or 1; x, y = 0-4; W = amino, carbamoyl, amidino, guanidino, heteroaryl, heterocyclyl, etc.] or their pharmaceutically-acceptable salts or prodrugs were prepd. as modulators of melanocortin receptors, particularly MC-1R and MC-4R. Thus, peptide I was prepd. by a soln.-phase peptide coupling/deprotection scheme.

L4 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2003 ACS
AN 2000:790471 CAPLUS
DN 133:350145
TI Preparation of cyclic amide compounds as chemokine receptor antagonists
IN Ishihara, Yuji; Imamura, Shinichi; Hashiguchi, Shohei; Nishimura, Osamu; Kanzaki, Naoyuki; Baba, Masanori
PA Takeda Chemical Industries, Ltd., Japan
SO PCT Int. Appl., 109 pp.
CODEN: PIXXD2
DT Patent
LA Japanese
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000066551	A1	20001109	WO 2000-JP2765	20000427
	W: AE, AG, AL, AM, AU, AZ, BA, BB, BG, BR, BY, CA, CN, CR, CU, CZ, DM, DZ, EE, GD, GE, HR, HU, ID, IL, IN, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LV, MA, MD, MG, MK, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, TJ, TM, TR, TT, UA, US, UZ, VN, YU, ZA, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	JP 2001011073	A2	20010116	JP 2000-132861	20000427
	EP 1180513	A1	20020220	EP 2000-921055	20000427
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
PRAI	JP 1999-122549	A	19990428		
	WO 2000-JP2765	W	20000427		

OS MARPAT 133:350145
GI



I

AB The title compds. I [R1 is hydrocarbyl and R2 is hydrocarbyl having two or more carbon atoms, or R1 and R2 together with the nitrogen atom adjacent thereto may form a ring which may be substituted; R3 is optionally substituted hydrocarbyl or a heterocyclic group; R4 is hydrogen, hydrocarbyl, a heterocyclic group, or the like; E is a divalent chain hydrocarbon group or the like; G is CO or SO2; J is nitrogen, a methine group, or the like; and Q and R are each a divalent C1-C3 chain hydrocarbon group or the like] are prepd. I exhibit excellent CCR5 antagonism and are useful as preventive or therapeutic drugs for HIV infection of human peripheral blood monocytes, particularly AIDS. In an vitro test for CCR5 antagonism, N-[3-(4-benzyl-1-piperidinyl)propyl]-1-

methyl-5-oxo-N-phenyl-3-pyrrolidinecarboxamide hydrochloride at 1 .mu.M gave 57% inhibition of binding of RANTES to the CCR5 receptors. Formulations are given.

RE.CNT 16 THERE ARE 16 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2003 ACS
AN 1986:442838 CAPLUS
DN 105:42838
TI Substituted pyrrolidinones and their use in treating reduced cerebral function
IN Weber, Karl Heinz; Schneider, Claus; Walther, Gerhard; Hinzen, Dieter; Kuhn, Franz Josef; Lehr, Erich; Ensinger, Helmut; Troeger, Wolfgang
PA Boehringer Ingelheim K.-G., Fed. Rep. Ger.
SO Ger. Offen., 27 pp.
CODEN: GWXXBX
DT Patent
LA German
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	DE 3420193	A1	19851205	DE 1984-3420193	19840530
	EP 163260	A1	19851204	EP 1985-106343	19850523
	EP 163260	B1	19880803		
	R: AT, BE, CH, DE, FR, GB, IT, LI, LU, NL, SE				
	AT 36151	E	19880815	AT 1985-106343	19850523
	US 4670456	A	19870602	US 1985-738152	19850524
	PL 144921	B1	19880730	PL 1985-253668	19850528
	FI 8502130	A	19851201	FI 1985-2130	19850529
	FI 78462	B	19890428		
	FI 78462	C	19890810		
	DK 8502396	A	19851201	DK 1985-2396	19850529
	NO 8502133	A	19851202	NO 1985-2133	19850529
	HU 37751	A2	19860228	HU 1985-2056	19850529
	HU 193393	B	19870928		
	DD 235256	A5	19860430	DD 1985-276752	19850529
	ES 543592	A1	19860601	ES 1985-543592	19850529
	ZA 8504072	A	19870225	ZA 1985-4072	19850529
	SU 1360583	A3	19871215	SU 1985-3900955	19850529
	IL 75339	A1	19880731	IL 1985-75339	19850529
	CS 261883	B2	19890210	CS 1985-3854	19850529
	CA 1255664	A1	19890613	CA 1985-482660	19850529
	AU 8543170	A1	19851205	AU 1985-43170	19850530
	AU 581438	B2	19890223		
	JP 61000068	A2	19860106	JP 1985-117657	19850530
	JP 05017904	B4	19930310		
	ES 552410	A1	19870901	ES 1986-552410	19860226
	ES 552411	A1	19870901	ES 1986-552411	19860226
	ES 552409	A1	19871216	ES 1986-552409	19860226
	US 4762832	A	19880809	US 1986-943532	19861218
	US 4857528	A	19890815	US 1988-183819	19880420
	US 4891378	A	19900102	US 1989-365169	19890612
PRAI	DE 1984-3420193		19840530		
	EP 1985-106343		19850523		
	US 1985-738152		19850524		
	US 1986-943532		19861218		
	US 1988-183819		19880420		

OS CASREACT 105:42838
GI



I



II

AB Pyrrolidinones I [R1 = pyridyl, (un)substituted Ph; R2 = H, alkyl; R3 = alkyl, hydroxyalkyl, Ph (un)substituted by Cl, Br, Me, or MeO, cyclohexyl, dialkylaminoalkyl; R4 = H, alkyl; R3R4N = piperidino, morpholino, or piperazine (un)substituted by Me, piperazine 4-substituted by Ph, ClC6H4, or PhCH2 nortropanyl] and their physiol. tolerable acid addn. salts, useful as brain-protective agents at 100 mg/kg orally (hypoxia tolerance test), were prepd by 4 methods. 4-Aminoethyl-1-benzyl-2-pyrrolidinone in dioxane was treated with chlorocarbonylmethylpiperazine and the product treated with 2N NaOH to alky. to give 70% II. Pharmaceutical formulations contg. I were given.

AN 1986:442838 CAPLUS
DN 105:42838
TI Substituted pyrrolidinones and their use in treating reduced cerebral function
IN Weber, Karl Heinz; Schneider, Claus; Walther, Gerhard; Hinzen, Dieter; Kuhn, Franz Josef; Lehr, Erich; Ensinger, Helmut; Troeger, Wolfgang
PA Boehringer Ingelheim K.-G., Fed. Rep. Ger.
SO Ger. Offen., 27 pp.
CODEN: GWXXBX
DT Patent
LA German
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	DE 3420193	A1	19851205	DE 1984-3420193	19840530
	EP 163260	A1	19851204	EP 1985-106343	19850523
	EP 163260	B1	19880803		
	R: AT, BE, CH, DE, FR, GB, IT, LI, LU, NL, SE				
	AT 36151	E	19880815	AT 1985-106343	19850523
	US 4670456	A	19870602	US 1985-738152	19850524
	PL 144921	B1	19880730	PL 1985-253668	19850528
	FI 8502130	A	19851201	FI 1985-2130	19850529
	FI 78462	B	19890428		
	FI 78462	C	19890810		
	DK 8502396	A	19851201	DK 1985-2396	19850529
	NO 8502133	A	19851202	NO 1985-2133	19850529
	HU 37751	A2	19860228	HU 1985-2056	19850529
	HU 193393	B	19870928		
	DD 235256	A5	19860430	DD 1985-276752	19850529
	ES 543592	A1	19860601	ES 1985-543592	19850529
	ZA 8504072	A	19870225	ZA 1985-4072	19850529
	SU 1360583	A3	19871215	SU 1985-3900955	19850529
	IL 75339	A1	19880731	IL 1985-75339	19850529
	CS 261883	B2	19890210	CS 1985-3854	19850529
	CA 1255664	A1	19890613	CA 1985-482660	19850529
	AU 8543170	A1	19851205	AU 1985-43170	19850530
	AU 581438	B2	19890223		
	JP 61000068	A2	19860106	JP 1985-117657	19850530
	JP 05017904	B4	19930310		
	ES 552410	A1	19870901	ES 1986-552410	19860226
	ES 552411	A1	19870901	ES 1986-552411	19860226
	ES 552409	A1	19871216	ES 1986-552409	19860226
	US 4762832	A	19880809	US 1986-943532	19861218
	US 4857528	A	19890815	US 1988-183819	19880420
	US 4891378	A	19900102	US 1989-365169	19890612
PRAI	DE 1984-3420193		19840530		
	EP 1985-106343		19850523		
	US 1985-738152		19850524		
	US 1986-943532		19861218		
	US 1988-183819		19880420		

OS CASREACT 105:42838
GI



I



II

AB Pyrrolidinones I [R1 = pyridyl, (un)substituted Ph; R2 = H, alkyl; R3 = alkyl, hydroxyalkyl, Ph (un)substituted by Cl, Br, Me, or MeO, cyclohexyl, dialkylaminoalkyl; R4 = H, alkyl; R3R4N = piperidino, morpholino, or piperazine (un)substituted by Me, piperazine 4-substituted by Ph, ClC6H4, or PhCH2 nortropanyl] and their physiol. tolerable acid addn. salts, useful as brain-protective agents at 100 mg/kg orally (hypoxia tolerance test), were prepd by 4 methods. 4-Aminoethyl-1-benzyl-2-pyrrolidinone in dioxane was treated with chlorocarbonylmethylpiperazine and the product treated with 2N NaOH to alky. to give 70% II. Pharmaceutical formulations contg. I were given.

=> d hitstr 3

L4 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2003 ACS
IT **103296-26-0P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of, for cerebral insufficiency treatment)
RN 103296-26-0 CAPLUS
CN 1-Piperidinecarboxamide, N-[[5-oxo-1-(phenylmethyl)-3-pyrrolidinyl]methyl]- (9CI) (CA INDEX NAME)



AN 1976:108310 CAPLUS
DN 84:108310
TI Carboxypyrrolidinone-based lubricant additives
IN Elliott, John Scotchford; Davis, Bryan Terence; Norman, Stephen
PA Cooper, Edwin, and Co., UK
SO Ger. Offen., 51 pp.
CODEN: GWXXBX
DT Patent
LA German
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	DE 2444396	A1	19750320	DE 1974-2444396	19740917
	GB 1483457	A	19770817	GB 1973-43735	19740913
	BE 820011	A1	19750116	BE 1974-148612	19740917
	NO 7403339	A	19750319	NO 1974-3339	19740917
	SE 7411701	A	19750319	SE 1974-11701	19740917
	NL 7412304	A	19750320	NL 1974-12304	19740917
	FR 2243959	A1	19750411	FR 1974-31355	19740917
	DK 7404893	A	19750602	DK 1974-4893	19740917
	JP 50076104	A2	19750621	JP 1974-107586	19740917
	BR 7407728	A0	19750729	BR 1974-728	19740917
	AU 7473405	A1	19760325	AU 1974-73405	19740917
	ZA 7405891	A	19760428	ZA 1974-5891	19740917
	CA 1047198	A1	19790123	CA 1974-209369	19740917
	US 4127493	A	19781128	US 1977-854327	19771123
PRAI	GB 1973-43735		19730918		
	US 1974-506910		19740917		

AB Ash-free detergents for lubricating oils are prepd. by reacting substituted carboxypyrrolidinones with high-mol.-wt. dicarboxylic anhydrides. For example, 173.2 g of 1-(2-hydroxyethyl)-5-oxo-3-pyrrolidinecarboxylic acid (I) [43094-95-7] prepd. from 5.0 moles itaconic acid [97-65-4] and 50 moles ethanolamine [141-43-5] was heated with 1.0 mole diethanolamine [111-42-2] to give the N,N-bis(2-hydroxyethyl) amide of I (II) [58506-15-3], which had N content 10.4%, acid no. 5.6, and base no. 168.2 mg KOH/g. A mixt. of II 234.3, polyisobutenylsuccinic anhydride (polyisobutene mol. wt. 1,000) 1212.3, mineral oil 143, and toluenesulfonic acid 1.4 g was polymd. 9 hr at 185-210.degree. with removal of water to give a polyester, which, when purified, had N content 1.2%, acid no. 1.7, base no. 15.6, and sapon. no. 64.5 mg KOH/g. Tests in lubricating oil gave the following results: MS-VC sludge 7.1; lacquer 7.4; piston sheath lacquer 7.5; Petter AV-B piston ring groove coking 60.6, 0.4, none, overall 76.1; panel coker test, 61.0; and spot test A.

IT **58505-97-8P 58505-99-0P 58506-00-6P**
58506-01-7P 58506-02-8P 58506-03-9P
58506-04-0P 58506-05-1P 58506-07-3P
58506-12-0P
RL: PREP (Preparation)
(prepn. and polymn. with succinic anhydride derivs.)

RN 58505-97-8 CAPLUS
CN 3-Pyrrolidinecarboxamide, N-[3-[bis(2-hydroxyethyl)amino]propyl]-5-oxo- (9CI) (CA INDEX NAME)



RN 58505-99-0 CAPLUS
CN 3-Pyrrolidinecarboxamide, N-[3-[bis(2-hydroxyethyl)amino]propyl]-1-[2-hydroxy-1,1-bis(hydroxymethyl)ethyl]-5-oxo- (9CI) (CA INDEX NAME)



RN 58506-00-6 CAPLUS
CN 3-Pyrrolidinecarboxamide, N-[3-[bis(2-hydroxyethyl)amino]propyl]-1-(2-hydroxyethyl)-5-oxo- (9CI) (CA INDEX NAME)



RN 58506-01-7 CAPLUS
CN 3-Pyrrolidinecarboxamide, 1-(2-hydroxyethyl)-N-[2-[(2-hydroxyethyl)amino]ethyl]-5-oxo- (9CI) (CA INDEX NAME)



RN 58506-02-8 CAPLUS
CN 3-Pyrrolidinecarboxamide, N,N'-1,2-ethanediylbis[1-(2-hydroxyethyl)-5-oxo- (9CI) (CA INDEX NAME)



RN 58506-03-9 CAPLUS
CN 3-Pyrrolidinecarboxamide, N-[3-[bis(2-hydroxyethyl)amino]propyl]-5-oxo-1-phenyl- (9CI) (CA INDEX NAME)



RN 58506-04-0 CAPLUS
CN 3-Pyrrolidinecarboxamide, N-[3-[bis(2-hydroxyethyl)amino]propyl]-1-octyl-5-oxo- (9CI) (CA INDEX NAME)



RN 58506-05-1 CAPLUS
CN 3-Pyrrolidinecarboxamide, 1-[3-[bis(2-hydroxyethyl)amino]propyl]-N-[3-(dimethylamino)propyl]-5-oxo- (9CI) (CA INDEX NAME)



RN 58506-07-3 CAPLUS
CN 3-Pyrrolidinecarboxamide, N-[3-[bis(2-hydroxyethyl)amino]propyl]-1-[3-[2-(2-hydroxyethoxy)ethoxy]propyl]-5-oxo- (9CI) (CA INDEX NAME)



RN 58506-12-0 CAPLUS
CN 3-Pyrrolidinecarboxamide, N,1-bis[3-[bis(2-hydroxyethyl)amino]propyl]-5-oxo- (9CI) (CA INDEX NAME)



=> d l3
L3 HAS NO ANSWERS
L3 STR



VAR G1=C/S
REP G2=(0-3) CH
VAR G3=H/C
NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RSPEC 1
NUMBER OF NODES IS 13

STEREO ATTRIBUTES: NONE

=> s l3 ful
FULL SEARCH INITIATED 13:51:01 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 970 TO ITERATE

100.0% PROCESSED 970 ITERATIONS 115 ANSWERS
SEARCH TIME: 00.00.01

L5 115 SEA SSS FUL L3




```
VAR G1=C/S
VAR G3=H/C
ENTER (DIS), GRA, NOD, BON OR ?:end
L7   STRUCTURE CREATED

=> search l7
ENTER TYPE OF SEARCH (SSS), CSS, FAMILY, OR EXACT:sss
ENTER SCOPE OF SEARCH (SAMPLE), FULL, RANGE, OR SUBSET:subset
ENTER SUBSET L# OR (END):end
SEARCH ENDED BY USER

=> struc
ENTER NAME OF STRUCTURE TO BE RECALLED (NONE):l7
ENTER (DIS), GRA, NOD, BON OR ?:end
L8   STRUCTURE CREATED

=> search l7
ENTER TYPE OF SEARCH (SSS), CSS, FAMILY, OR EXACT:sss
ENTER SCOPE OF SEARCH (SAMPLE), FULL, RANGE, OR SUBSET:subset
ENTER SUBSET L# OR (END):l5
L5  IS NOT A VALID L#
L-numbers must be in the range L1-L999.
ENTER SUBSET L# OR (END):l5
ENTER SUBSET SEARCH SCOPE - SAMPLE, FULL, RANGE, OR (END):ful
FULL SUBSET SEARCH INITIATED 13:57:56 FILE 'REGISTRY'
FULL SUBSET SCREEN SEARCH COMPLETED -     115 TO ITERATE

100.0% PROCESSED     115 ITERATIONS                              70 ANSWERS
SEARCH TIME: 00.00.01

L9            70 SEA SUB=L5 SSS FUL L7
```

=> s l9
L10 12 L9

=> s l12 and py<1999
L12 NOT FOUND
The L-number entered could not be found. To see the definition
of L-numbers, enter DISPLAY HISTORY at an arrow prompt (=>).

=> d bib abs 1-12

L10 ANSWER 1 OF 12 CAPLUS COPYRIGHT 2003 ACS
AN 2002:487577 CAPLUS
DN 137:63420
TI Preparation of lactone ketolide macrolide erythromycin antibiotics
IN Andreotti, Daniele; Arista, Luca; Biondi, Stefano; Cardullo, Francesca; Damiani, Frederica; Lociuro, Sergio; Marchioro, Carla; Merlo, Giancarlo; Mingardi, Anna; Niccolai, Daniela; Paio, Alfredo; Piga, Elisabetta; Pozzan, Alfonso; Seri, Catia; Tarsi, Luca; Terreni, Silvia; Tibasco, Jessica
PA Glaxo Group Limited, UK
SO PCT Int. Appl., 215 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002050091	A1	20020627	WO 2001-GB5665	20011220
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2002017277	A5	20020701	AU 2002-17277	20011220
PRAI	GB 2000-31309	A	20001221		
	GB 2001-26276	A	20011101		
	GB 2001-26277	A	20011101		
	WO 2001-GB5665	W	20011220		

OS MARPAT 137:63420
GI



I

AB The present invention relates to lactone ketolides I wherein R is H, CN,

substituted alkyl; R1 is alkyl, alkenyl; R2 is H, hydroxy protecting group; R3 is H, halogen, and pharmaceutically acceptable salts and solvates thereof, to process for their prepn. and their use in therapy or prophylaxis of systemic or topical bacterial infections in a human or animal body. Thus, (11S,21R)-3-decladinosyl-11,12-dideoxy-6-O-methyl-3-oxo-12,11-[oxycarbonyl-(cyano)-methylene]erythromycin A was prepd. and tested as antibacterial agent against Streptococcus pneumoniae and Streptococcus pyogenes (MIC .ltoreq. 1 .mu.g/mL).

RE.CNT 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 2 OF 12 CAPLUS COPYRIGHT 2003 ACS
AN 2001:453053 CAPLUS
DN 135:61230
TI 1-(Aminophenyl)-2-pyrrolidones as integrin inhibitors
IN Dominguez, Celia; Chen, Guoqing; Xi, Ning; Xu, Shimin; Han, Nianhe; Liu, Qingyian; Huang, Qi; Siegmund, Aaron; Handley, Michael; Liu, Longbin; Kiselyov, Alexander S.
PA Amgen Inc., USA
SO PCT Int. Appl., 197 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2001044230	A1	20010621	WO 2000-US33515	20001211
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
US 2002019402	A1	20020214	US 2000-732546	20001208
EP 1240158	A1	20020918	EP 2000-984165	20001211
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
PRAI US 1999-170824P	P	19991214		
WO 2000-US33515	W	20001211		

OS MARPAT 135:61230
GI



I

AB Title compds. are effective in the prophylaxis and treatment of diseases or conditions mediated by integrin receptors, such as .alpha.v.beta.3, .alpha.v.beta.5, .alpha.v.beta.6, .alpha.5.beta.1. Thus, the pyrrolidinone I [R = PhNHCO, R1 = H] was prepd. by treating I [R = H, R1 =

Et] with PhNCO and ester hydrolysis.
RE.CNT 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT .

L10 ANSWER 3 OF 12 CAPLUS COPYRIGHT 2003 ACS
AN 1997:464222 CAPLUS
DN 127:122478
TI Solvent-free curable liquid polymer compositions and manufacture of their cured products
IN Yamaguchi, Takeo; Kawashima, Yoshinori; Doi, Makoto; Kurihashi, Toru
PA Toyo Ink Mfg. Co., Ltd., Japan
SO Jpn. Kokai Tokkyo Koho, 7 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 09165445	A2	19970624	JP 1995-328534	19951218
PRAI	JP 1995-328534		19951218		

AB Title compns., useful for coatings, adhesives, inks, molding materials, etc., are obtained by reaction of (A) compds. having 2 (meth)acrylic groups per mol. 10-70, (B) compds. having having .gtoreq.3 (meth)acrylic groups per mol. 1-50, and (C) primary monoamines or secondary diamines 10-70%, wherein A, B, and/or C have lactam rings in their mols. The compns. are coated on substrates or charged in molds, then heated or irradiated with light or an electronic beam to cure the compns. Thus, NP-A (neopentyl glycol diacrylate) 16.9, TMP-A (trimethylolpropane triacrylate) 5.9, BuNH2 3.7, and N-(3-amino-2,2-dimethylpropyl)-1-butyl-5-oxo-3-pyrrolidinecaboxamide 12.8 g were treated in MeOH at room temp. for 12 h, then MeOH was removed to give a liq. resin with Mw 5000 and 40,000 cP at 50.degree.. The resin (5 g) was mixed with 0.05 g p-MeC6H4SO3H, applied on an Al plate and cured at 120.degree. for 1 h to give a tack-free membrane.

L10 ANSWER 4 OF 12 CAPLUS COPYRIGHT 2003 ACS
AN 1997:14597 CAPLUS
DN 126:59959
TI Preparation of tetrahydropyrimidine derivatives as insecticides
IN Oora, Takeshi; Nakaya, Michihiko; Oonuma, Kazutomi; Kawahara, Nobuyuki
PA Mitsui Toatsu Chemicals, Japan
SO Jpn. Kokai Tokkyo Koho, 19 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 08259562	A2	19961008	JP 1995-64119	19950323
PRAI	JP 1995-64119		19950323		

OS MARPAT 126:59959
GI



I

AB The title compds. [I; X1 - X9 = H, C1-4 alkyl; R1 = H, C1-5 alkyl, C1-6 alkyloxycarbonyl or alkylcarbonyl, etc.; Y = electron withdrawing group; R2 = H, C1-6 alkyl; Z = S(O)nR3, NR4R5; m = 1-3; R3 = (un)substituted alkyl or alkenyl or alkynyl, etc.; n = 0-2; R4, R5 = (un)substituted alkyl or alkenyl or alkynyl or aryl, etc.; or R4 and R5 combine with an adjacent N to form a cycloamino] are prepd. Insecticides contg. I are useful against Laodelphax striatellus, Spodoptera litura, and Nephotettix cincticeps. Thus, 1-(tetrahydro-3'-furanylmethyl)-2-(nitromethylene)imidazoline was refluxed with HCHO and p-MeC6H4SH in EtOH to give 40% I (X1 - X9 = R1 = R2 = H, n = 2, Y = NO2, Z = p-MeC6H4S) (II). II at 10 ppm killed 100% of N. cincticeps vs. 0% of ref. compd. 1-[(1'-methyl-3'-pyrrolinyl)methyl]-2-nitromethyleneimidazoline.

L10 ANSWER 5 OF 12 CAPLUS COPYRIGHT 2003 ACS
AN 1995:837443 CAPLUS
DN 123:229354
TI Pyrrolidone group-containing polyamides and polyamide-polyesters
IN Nguyen, Kim Son; Breitenbach, Joerg; Sanner, Axel; Hoessel, Peter; Lang, Siegfried
PA BASF A.-G., Germany
SO Ger. Offen., 20 pp.
CODEN: GWXXBX
DT Patent
LA German
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	DE 4333238	A1	19950406	DE 1993-4333238	19930930
	WO 9509194	A1	19950406	WO 1994-EP3141	19940920
	W: CA, JP, US				
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	CA 2172987	AA	19950406	CA 1994-2172987	19940920
	EP 721478	A1	19960717	EP 1994-927632	19940920
	R: AT, CH, DE, DK, ES, FR, GB, IE, IT, LI, NL, PT, SE				
	JP 09505330	T2	19970527	JP 1994-510093	19940920
	US 5880252	A	19990309	US 1996-619731	19960322
PRAI	DE 1993-4333238		19930930		
	WO 1994-EP3141		19940920		

AB The title polymers HX(AZCOX)nH, HNR(ANRCOZBZCONR)nH, or HX(AXCOZACOX)nH (X = O, NR; A = alkylene, cycloalkylene, arylene, etc.; Z = pyrrolidin-2-one-1,4-diyl; B = alkylene, cycloalkylene, etc.; n = 5-500) are prepd. by reacting a pyrrolidone deriv. such as 4-carboxy-1-(2-hydroxyethyl)pyrrolidin-2-one or 1,2-bis(4-carboxy-2-oxopyrrolidin-1-yl)ethane (I) (e.g., prepd. by cyclization of itaconic acid with HOCH2CH2NH2 and H2NCH2CH2NH2, resp.) with an amino alc. or diamine HXANH2. The polymers are useful as hair conditioners, stabilizers for enzymes and bleaching agents in detergent compns., etc. A polyamide was prepd. from I and H2NCH2CH2NH2.

L10 ANSWER 6 OF 12 CAPLUS COPYRIGHT 2003 ACS
AN 1986:131441 CAPLUS
DN 104:131441
TI Heterocyclic compounds containing basic and/or cationic groups and azo dyes prepared from them
IN Pedrazzi, Reinhard
PA Sandoz-Patent-G.m.b.H., Fed. Rep. Ger.
SO Ger. Offen., 71 pp.
CODEN: GWXXBX
DT Patent
LA German
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE

PI	DE 3503844	A1	19850814	DE 1985-3503844	19850205
	FR 2559483	A1	19850816	FR 1985-1755	19850206
	FR 2559483	B1	19861205		
	GB 2153835	A1	19850829	GB 1985-3089	19850207
	GB 2153835	B2	19871028		
	CH 663614	A	19871231	CH 1985-548	19850207
	US 4686285	A	19870811	US 1985-699916	19850208
	JP 60184563	A2	19850920	JP 1985-23677	19850212
	JP 06074383	B4	19940921		
PRAI	DE 1984-3404778		19840210		

GI



I



II

AB Compds. of general structure I (p = 1, Q = H) and their azo derivs. (I; p = 1, 2; Q = diazo or tetrazo component residue; metal-free or metalized) are prepd., where R = O, NH, or S; R1 = C1-4 alkyl, alkoxy, CO2H, etc.; R2 = OH, (un)substituted NH2, alkoxy, phenoxy, pyrazoline-contg. group, or R3; R3 = through-N-bound org. radical contg. 1-5 N atoms, one of more of which is basic or in ammonium form; Z = (un)substituted arylene; Z1 = bivalent bridging group; Z2 = (un)substituted NH or 1,4-piperazinediyl; a = 0 or 1; and x = 0 or 1 (a + x = 1 or 2). The azo derivs. (in salt form) are fast dyes for paper, cotton, and leather. Thus, reaction of cyanuric chloride with Et2N(CH2)3NH2 and then 1-(4-aminophenyl)-3-methyl-5-pyrazolone gave II (Q = H) (III). Coupling of III with diazotized 2-(4-aminophenyl)-6-methylbenzothiazole gave II [Q = 4-(6-methyl-.alpha.-benzothiazolyl)phenylazo], a yellow powder which, in the form of an acid salt, dyed paper in clear, yellow shades. Numerous other couplers and azo dyes were prepd.

L10 ANSWER 7 OF 12 CAPLUS COPYRIGHT 2003 ACS
AN 1981:156762 CAPLUS
DN 94:156762
TI Piperidinylpyrrolidinones
PA Ciba-Geigy A.-G., Switz.
SO Jpn. Kokai Tokkyo Koho, 21 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE

PI	JP 55147277	A2	19801117	JP 1980-57043	19800428
	EP 20293	A1	19801210	EP 1980-810132	19800421
	EP 20293	B1	19840523		
	R: BE, CH, DE, FR, GB, IT, NL				
	US 4309546	A	19820105	US 1980-143387	19800424
PRAI	CH 1979-3991		19790427		

GI



I

AB Pyrrolidinones I [R = H, alkyl, aralkyl, etc.; R1 = alkoxy, (un)substituted amino, OH, etc.; X = a bond or connecting group, e.g., alkylene] or their oligomers were prepd. Thus, 68.2 g 1,2,2,6,6-pentamethyl-4-aminopiperidine was refluxed with 83.2 g di-Me itaconate for 19 h to give I (R = Me, R1 = MeO, X = bond) (no yield given).

L10 ANSWER 8 OF 12 CAPLUS COPYRIGHT 2003 ACS
AN 1978:154338 CAPLUS
DN 88:154338
TI Dyes for keratin-containing substances
IN Kalopissis, Gregoire; Zysmann, Alexandre; Bugaut, Andree; Sebag, Henri; Vanlerberghe, Guy; Huron, Jean Louis
PA Oreal S. A., Fr.
SO Ger. Offen., 57 pp.
CODEN: GWXXBX
DT Patent
LA German
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	DE 2736266	A1	19780216	DE 1977-2736266	19770811
	DE 2736266	C2	19900906		
	FR 2361447	A1	19780310	FR 1976-24618	19760812
	FR 2361447	B1	19781222		
	US 4228259	A	19801014	US 1977-822912	19770808
	BE 857664	A1	19780210	BE 1977-180064	19770810
	ES 461506	A1	19781216	ES 1977-461506	19770810
	AU 7727766	A1	19790215	AU 1977-27766	19770810
	SE 7709083	A	19780213	SE 1977-9083	19770811
	DK 7703572	A	19780213	DK 1977-3572	19770811
	BR 7705325	A	19780530	BR 1977-5325	19770811
	GB 1589589	A	19810513	GB 1977-33783	19770811
	GB 1589590	A	19810513	GB 1978-40691	19770811
	CA 1107724	A1	19810825	CA 1977-284640	19770811
	NL 7708936	A	19780214	NL 1977-8936	19770812
	JP 53041321	A2	19780414	JP 1977-96177	19770812
	DK 8000494	A	19800205	DK 1980-494	19800205
PRAI	FR 1976-24618		19760812		
	DK 1977-3572		19770811		

AB Water-sol., cationic polymers contg. secondary or tertiary amino or quaternary ammonium groups and aryl or arylaliph. chromophoric groups are prepd. and used as nontoxic dyes with high affinity for the surface of

human hair. For example, addn. of 7.3 g (0.0196 mol) 1-[[3-(2-chloroacetamido)propyl]amino]-4-hydroxyanthraquinone in .apprx.50 mL DMF to 6 g (0.0324 base equiv) [NHCH2CH2NHCH2CH2NHCO(CH2)4CO]n in 10 mL Me Cellosolve, heating 3 h at 80.degree., and neutralizing with methanolic NaOMe gave 60% polymeric dye (I). A mixt. of 0.18 g I, 1.5 g 90:10 vinyl acetate-crotonic acid copolymer, 0.25 g 60:40 vinylpyrrolidone-vinyl acetate copolymer, EtOH, triethanolamine (to adjust to pH 7), and H2O to 100 mL imparted an iridescent ash-colored luster to light chestnut brown hair.

L10 ANSWER 9 OF 12 CAPLUS COPYRIGHT 2003 ACS
AN 1976:542989 CAPLUS
DN 85:142989
TI 1-(Bistrifluoromethylphenyl)-2-oxopyrrolidine-4-carboxylic acid derivatives for use as plant growth regulators and herbicides
IN Bellus, Daniel; Foery, Werner
PA Ciba-Geigy A.-G., Switz.
SO Ger. Offen., 51 pp.
CODEN: GWXXBX
DT Patent
LA German
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	DE 2548231	A1	19760506	DE 1975-2548231	19751028
	CH 611773	A	19790629	CH 1974-14595	19741031
	DK 7504309	A	19760501	DK 1975-4309	19750925
	SE 7511210	A	19760503	SE 1975-11210	19751007
	SE 405852	C	19790419		
	SE 405852	B	19790108		
	US 4013445	A	19770322	US 1975-625234	19751023
	FR 2289498	A1	19760528	FR 1975-32902	19751028
	FR 2289498	B1	19780922		
	NL 7512672	A	19760504	NL 1975-12672	19751029
	DD 124728	C	19770309	DD 1975-189104	19751029
	PL 102551	P	19790430	PL 1975-184337	19751029
	IL 48381	A1	19790725	IL 1975-48381	19751029
	CA 1083574	A1	19800812	CA 1975-238543	19751029
	BE 835040	A1	19760430	BE 1975-161395	19751030
	BR 7507116	A	19760803	BR 1975-7116	19751030
	ZA 7506836	A	19761027	ZA 1975-6836	19751030
	ES 442215	A1	19770416	ES 1975-442215	19751030
	AU 7586194	A1	19770505	AU 1975-86194	19751030
	AU 507492	B2	19800214		
	CS 193531	P	19791031	CS 1975-7331	19751030
	JP 51125745	A2	19761102	JP 1975-132080	19751031
PRAI	CH 1974-14595		19741031		

GI



I

AB Pyrrolidinones I [R = CO2R1 (R1 = H, alkyl, cycloalkyl, chloroalkyl,

alkoxyethyl, Ph, substituted phenyl, oxacycloalkylethyl, etc.), cyano, COSBu, COSPh, COR2 (R2 = NHCHEt2, NH2, NHNH2, N(CH2CH2OH)2, piperidinoamino, aziridino, allylamino, etc.) CO2- 0.5 M++ [M = Cu, Zn, H3N(CH2)mNH3 (n = 2, 6, 10), Et2NH(CH2)2NHEt2, etc.], CO2- M+ (M = NBu4, NMe3CH2Ph, NH4, NHMe2CH2CH2Cl, etc.] (62 compds.), useful as herbicides and plant growth regulators, were prepd. by cyclizing 3,5-(F3C)2C6H3NH2 with itaconic acid to give I (R = CO2H), then treating this free acid or its reactive derivs. with alcs., alkyl halides, or amines by known methods to give I [R = CO2R1 (R1 .noteq. H)]. At 5 kg/ha, I (R = CO2Me) gave grass hts. at 1, 4, and 12 weeks after application (control hts. in parentheses): 10(12), 12(23), 17 cm (59 cm).

L10 ANSWER 10 OF 12 CAPLUS COPYRIGHT 2003 ACS
AN 1976:108310 CAPLUS
DN 84:108310
TI Carboxypyrrolidinone-based lubricant additives
IN Elliott, John Scotchford; Davis, Bryan Terence; Norman, Stephen
PA Cooper, Edwin, and Co., UK
SO Ger. Offen., 51 pp.
CODEN: GWXXBX
DT Patent
LA German
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	DE 2444396	A1	19750320	DE 1974-2444396	19740917
	GB 1483457	A	19770817	GB 1973-43735	19740913
	BE 820011	A1	19750116	BE 1974-148612	19740917
	NO 7403339	A	19750319	NO 1974-3339	19740917
	SE 7411701	A	19750319	SE 1974-11701	19740917
	NL 7412304	A	19750320	NL 1974-12304	19740917
	FR 2243959	A1	19750411	FR 1974-31355	19740917
	DK 7404893	A	19750602	DK 1974-4893	19740917
	JP 50076104	A2	19750621	JP 1974-107586	19740917
	BR 7407728	A0	19750729	BR 1974-728	19740917
	AU 7473405	A1	19760325	AU 1974-73405	19740917
	ZA 7405891	A	19760428	ZA 1974-5891	19740917
	CA 1047198	A1	19790123	CA 1974-209369	19740917
	US 4127493	A	19781128	US 1977-854327	19771123
PRAI	GB 1973-43735		19730918		
	US 1974-506910		19740917		

AB Ash-free detergents for lubricating oils are prepd. by reacting substituted carboxypyrrolidinones with high-mol.-wt. dicarboxylic anhydrides. For example, 173.2 g of 1-(2-hydroxyethyl)-5-oxo-3-pyrrolidinecarboxylic acid (I) [43094-95-7] prepd. from 5.0 moles itaconic acid [97-65-4] and 50 moles ethanolamine [141-43-5] was heated with 1.0 mole diethanolamine [111-42-2] to give the N,N-bis(2-hydroxyethyl) amide of I (II) [58506-15-3], which had N content 10.4%, acid no. 5.6, and base no. 168.2 mg KOH/g. A mixt. of II 234.3, polyisobutenylsuccinic anhydride (polyisobutene mol. wt. 1,000) 1212.3, mineral oil 143, and toluenesulfonic acid 1.4 g was polymd. 9 hr at 185-210.degree. with removal of water to give a polyester, which, when purified, had N content 1.2%, acid no. 1.7, base no. 15.6, and sapon. no. 64.5 mg KOH/g. Tests in lubricating oil gave the following results: MS-VC sludge 7.1; lacquer 7.4; piston sheath lacquer 7.5; Petter AV-B piston ring groove coking 60.6, 0.4, none, overall 76.1; panel coker test, 61.0; and spot test A.

L10 ANSWER 11 OF 12 CAPLUS COPYRIGHT 2003 ACS
AN 1973:43180 CAPLUS
DN 78:43180
TI Synthesis and pharmacological properties of new derivatives of 2-pyrrolidone-4-carboxylic acid

AU Buzas, Andre; Egnell, Christian; Bourillet, Francois; Linee, Philippe; Simon, Jean Claude
CS Lab. Chim. V., Fac. Sci., Orleans-La Source, Fr.
SO Chimica Therapeutica (1972), 7(5), 398-403
CODEN: CHTPBA; ISSN: 0009-4374
DT Journal
LA French
AB The 2-pyrrolidone-4-carboxamides I (R = Ph, NHPh, CH2Ph, C6H4Cl-p, C6H4OH-p, C6H4OMe-p, C6H4CF3-m, C6H4CO2Me-.omicron., cyclohexyl; R1 = NHCMe3, NH(CH2)2NEt2, NH(CH2)3NMe2, morpholino, piperidino, 4-methyl-1-piperazinyl, 4-piperonyl-1-piperazinyl, NHC6H4COR2-o; R2 = OH, NHOH, OMe, morpholino, piperidino, NHCMe3) were prepd. by cyclizing itaconic acid with RNH2 and forming the amides with R1H and dicyclohexylcarbodiimide. I are sedatives, muscle relaxants, analgesics, and anti-inflammatories, and I [R = Ph, R1 = NH(CH2)3NMe2] also had antiarrhythmic properties.

L10 ANSWER 12 OF 12 CAPLUS COPYRIGHT 2003 ACS
AN 1970:415332 CAPLUS
DN 73:15332
TI Reactions and applications of itaconic acid. XV. Synthesis of heat resistant polymers from the reaction products between itaconic acid and two aromatic diamines
AU Akashi, Hiroyoshi
CS Dep. Ind. Chem., Kobe Univ., Kobe, Japan
SO Memoirs of the Faculty of Engineering, Kobe University (1970), No. 16, 162-74
CODEN: MFEKAF; ISSN: 0368-9638
DT Journal
LA English
AB p,p'-Bis(4-carboxy - 2-oxo-1-pyrrolidinyl)biphenyl (I) and p-bis(4-carboxy-2-oxo - 1-pyrrolidinyl)benzene (II) were prepd. by heating itaconic acid with benzidine or p-phenylenediamine in H2O or H2O-EtOH mixt. Polycondensation of I or II with 3,3'-diaminobenzidine in polyphosphoric acid gave yellow powd. resins with very high thermal stability. The structure of the resins resembled that of a pyrrolidinonyl-substituted polybenzimidazole.

d l12
L12 HAS NO ANSWERS
L12 STR



VAR G1=C/S
REP G2=(2-3) CH
NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RSPEC 1
NUMBER OF NODES IS 11

STEREO ATTRIBUTES: NONE

=> s l12 ful
FULL SEARCH INITIATED 14:01:41 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 37100 TO ITERATE

100.0% PROCESSED 37100 ITERATIONS 64 ANSWERS
SEARCH TIME: 00.00.03

L14 64 SEA SSS FUL L12

=> d l16
L16 HAS NO ANSWERS
L16 STR



VAR G1=C/S
REP G2=(2-3) CH
NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RSPEC 1
NUMBER OF NODES IS 11

STEREO ATTRIBUTES: NONE

=> search l16
ENTER TYPE OF SEARCH (SSS), CSS, FAMILY, OR EXACT:sss
ENTER SCOPE OF SEARCH (SAMPLE), FULL, RANGE, OR SUBSET:subset
ENTER SUBSET L# OR (END):l14
ENTER SUBSET SEARCH SCOPE - SAMPLE, FULL, RANGE, OR (END):ful
FULL SUBSET SEARCH INITIATED 14:04:00 FILE 'REGISTRY'
FULL SUBSET SCREEN SEARCH COMPLETED - 27 TO ITERATE

100.0% PROCESSED 27 ITERATIONS 18 ANSWERS
SEARCH TIME: 00.00.01

L17 18 SEA SUB=L14 SSS FUL L16

```
=> s l17
L18           8 L17

=> d bib 1-8

L18  ANSWER 1 OF 8  CAPLUS  COPYRIGHT 2003 ACS
AN   2001:338479  CAPLUS
DN   134:353175
TI   Preparation of amides and ureas as activators of soluble guanylate cyclase
IN   Selwood, David; Glen, Robert; Reynolds, Karen; Wishart, Grant
PA   University College London, UK
SO   PCT Int. Appl., 101 pp.
     CODEN: PIXXD2
DT   Patent
LA   English
FAN.CNT 1
     PATENT NO.         KIND  DATE           APPLICATION NO.  DATE
     ---------------    ----  --------       ---------------  --------
PI   WO 2001032604      A1    20010510       WO 2000-GB4249   20001106
         W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
             CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR,
             HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT,
             LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU,
             SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN,
             YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
         RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,
             DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,
             BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
     EP 1237849          A1    20020911       EP 2000-973061   20001106
         R:  AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
             IE, SI, LT, LV, FI, RO, MK, CY, AL, TR
PRAI GB 1999-26286      A     19991105
     US 2000-201382P    P     20000502
     WO 2000-GB4249     W     20001106
OS   MARPAT 134:353175
RE.CNT  24     THERE ARE 24 CITED REFERENCES AVAILABLE FOR THIS RECORD
               ALL CITATIONS AVAILABLE IN THE RE FORMAT

L18  ANSWER 2 OF 8  CAPLUS  COPYRIGHT 2003 ACS
AN   2000:314542  CAPLUS
DN   132:308252
TI   Preparation of dihydropyridinones and pyrrolinones useful as alpha 1a
     adrenoceptor antagonists
IN   Barrow, James; Selnick, Harold G.; Nanterment, Philippe G.
PA   Merck & Co., Inc., USA
SO   PCT Int. Appl., 112 pp.
     CODEN: PIXXD2
DT   Patent
LA   English
FAN.CNT 1
     PATENT NO.         KIND  DATE           APPLICATION NO.  DATE
     ---------------    ----  --------       ---------------  --------
PI   WO 2000025782      A1    20000511       WO 1999-US24990  19991025
         W:  AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU,
             CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL,
             IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD,
             MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK,
             SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ,
             BY, KG, KZ, MD, RU, TJ, TM
         RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE,
             DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF,
             CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
```

	US 6235759	B1	20010522	US 1999-428973	19991028
PRAI	US 1998-106095P	P	19981029		
	US 1999-141463P	P	19990629		

OS MARPAT 132:308252
RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L18 ANSWER 3 OF 8 CAPLUS COPYRIGHT 2003 ACS
AN 1996:644105 CAPLUS
DN 125:275906
TI Preparation of (pyridonyl)sulfonylurea herbicides
IN Morishima, Yasuo; Murai, Shigeo; Aoyama, Yoshiyuki; Sasaki, Hiroshi; Kikugawa, Hiroshi; Nagayama, Soichiro; Mitani, Makiko
PA Ishihara Sangyo Kaisha, Ltd., Japan
SO Eur. Pat. Appl., 121 pp.
CODEN: EPXXDW
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 733629	A1	19960925	EP 1996-103899	19960312
	R: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
	US 5869428	A	19990209	US 1996-610490	19960304
	CA 2171251	AA	19960914	CA 1996-2171251	19960307
	JP 08311062	A2	19961126	JP 1996-84751	19960312
	BR 9600992	A	19971230	BR 1996-992	19960312
	CN 1139109	A	19970101	CN 1996-103107	19960313
PRAI	JP 1995-81740		19950313		

OS MARPAT 125:275906

L18 ANSWER 4 OF 8 CAPLUS COPYRIGHT 2003 ACS
AN 1991:199047 CAPLUS
DN 114:199047
TI New aminothiazolylglycylcephalosporins with a 1,5-dihydroxy-4-pyridone-2-carbonyl group. I. Synthesis and biological activity of cephalosporin derivatives leading to MT0703
AU Ogino, Hiroko; Iwamatsu, Katsuyoshi; Katano, Kiyoaki; Nakabayashi, Satoru; Yoshida, Takashi; Tsuruoka, Takashi; Inouye, Shigeharu; Kondo, Shinichi
CS Pharm. Res. Cent., Meiji Seika Kaisha, Ltd., Yokohama, 222, Japan
SO Journal of Antibiotics (1990), 43(2), 174-88
CODEN: JANTAJ; ISSN: 0021-8820
DT Journal
LA English
OS CASREACT 114:199047

L18 ANSWER 5 OF 8 CAPLUS COPYRIGHT 2003 ACS
AN 1966:403904 CAPLUS
DN 65:3904
OREF 65:681f-g
TI Cyanomethyl esters. VI. Reactions of cyanomethyl N-methyl-2-pyridone-5-carboxylate with ammonia and amines
AU Grudzinski, Stefan
CS Akad. Med., Lodz, Pol.
SO Roczniki Chem. (1966), 40(2), 335-7
DT Journal
LA Polish

L18 ANSWER 6 OF 8 CAPLUS COPYRIGHT 2003 ACS
AN 1966:104044 CAPLUS
DN 64:104044
OREF 64:19549f

TI Basic 2-piperidinones as potential central nervous depressants and anticholinergics
AU Bishop, D. C.; Cavalla, J. F.
CS Parke, Davis Co., Hounslow, UK
SO J. Chem. Soc., C, Org. (1966), (9), 802-5
DT Journal
LA English

L18 ANSWER 7 OF 8 CAPLUS COPYRIGHT 2003 ACS
AN 1966:4030 CAPLUS
DN 64:4030
OREF 64:685g-h
TI 2-Pyridones. 1-(Heterocyclic)-1,2-dihydro-2-oxopyridine-5-carboxylic acids and derivatives
AU Casola, Armand R.; Anderson, Floyd E.
CS Wallace & Tiernan, Inc., Rochester, NY
SO J. Pharm. Sci. (1965), 54(11), 1686-8
DT Journal
LA English

L18 ANSWER 8 OF 8 CAPLUS COPYRIGHT 2003 ACS
AN 1966:4029 CAPLUS
DN 64:4029
OREF 64:685f-g
TI Constituents of Mikania cordata. Isolation of mikanin, epifriedelinol, and fumaric acid; the structure of mikanin
AU Kiang, A. K.; Sim, K. Y.; Goh, J.
CS Univ. Singapore
SO J. Chem. Soc. (1965), (Nov.), 6371-4
DT Journal
LA English